#  @NattaCop TheUrbanFarmer TheUrbanFarmer posts on X about $ocgn, ocgn, money, company the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours. ### Engagements: [-----] [#](/creator/twitter::1487028804971155457/interactions)  - [--] Week [------] +25% - [--] Month [------] +312% - [--] Months [-------] +33% - [--] Year [-------] -7.10% ### Mentions: [--] [#](/creator/twitter::1487028804971155457/posts_active)  - [--] Week [--] +100% - [--] Month [--] +113% - [--] Months [--] +53% - [--] Year [---] +73% ### Followers: [-----] [#](/creator/twitter::1487028804971155457/followers)  - [--] Week [-----] +0.81% - [--] Month [-----] +0.65% - [--] Months [-----] +8% - [--] Year [-----] +27% ### CreatorRank: [---------] [#](/creator/twitter::1487028804971155457/influencer_rank)  ### Social Influence **Social category influence** [finance](/list/finance) [countries](/list/countries) [stocks](/list/stocks) [technology brands](/list/technology-brands) [celebrities](/list/celebrities) [exchanges](/list/exchanges) [currencies](/list/currencies) [us election](/list/us-election) [social networks](/list/social-networks) [cryptocurrencies](/list/cryptocurrencies) **Social topic influence** [$ocgn](/topic/$ocgn) #7, [ocgn](/topic/ocgn), [money](/topic/money), [company](/topic/company), [japan](/topic/japan), [stocks](/topic/stocks), [pharma](/topic/pharma), [next gen](/topic/next-gen), [events](/topic/events), [imo](/topic/imo) **Top accounts mentioned or mentioned by** [@ocugen](/creator/undefined) [@moreflax](/creator/undefined) [@drsmusunuri](/creator/undefined) [@robertkennedyjr](/creator/undefined) [@rickabright](/creator/undefined) [@elonmusk](/creator/undefined) [@nattacop](/creator/undefined) [@awareofsilence](/creator/undefined) [@bsdyork](/creator/undefined) [@usfda](/creator/undefined) [@crisisparade](/creator/undefined) [@danibeckman](/creator/undefined) [@martymakary](/creator/undefined) [@realdonaldtrump](/creator/undefined) [@amldean19](/creator/undefined) [@bambossie81](/creator/undefined) [@cgtlive](/creator/undefined) [@pirateye2](/creator/undefined) [@un](/creator/undefined) [@scienceunga](/creator/undefined) **Top assets mentioned** [Novartis AG (NVS)](/topic/novartis) [Stellar (XLM)](/topic/stellar) [Pfizer, Inc. (PFE)](/topic/pfizer) [Verge (XVG)](/topic/verge) [Fusion (FSN)](/topic/fusion) [Alphabet Inc Class A (GOOGL)](/topic/google) [Spotify Technology (SPOT)](/topic/spotify) ### Top Social Posts Top posts by engagements in the last [--] hours "$ocgn Come step outta your shoes for a second. Might just realize why certain ppl act a certain way. Can you guess who owns these shoes 🤭 Imagine you sell covered calls shares locked up at a strike price and expiration date. You're confident in your strategy to generate" [X Link](https://x.com/NattaCop/status/1674534301483008000) 2023-06-29T21:48Z [---] followers, [----] engagements "I believe it 💪 just watch out for the snakes in the grass who have incentives to spread that sort of fud. Sorry if I was blunt its just Ive been here since this company went public(check out my vid Dj vu where I showcase these same fears that were being spread back in 2019/2020 before the 🚀 to ATH). Ive been through RS fears before and have heard all the fud imaginable too many times to count. Most of the time facts can easily disprove the fud. Fact is Ocugen has plenty of time to regain compliance I was here during the only RS vote in the companies history and that vote only came at the" [X Link](https://x.com/NattaCop/status/1689674787113865216) 2023-08-10T16:27Z [---] followers, [---] engagements "@RickABright Exactly Rick. Its a shame to see such results after all that. We urgently need to fund fresh cost-effective platforms with ethical companies that value people over profits. Time to pivot towards innovation that helps all and guarantees fair access to life-saving solutions" [X Link](https://x.com/NattaCop/status/1690844048628879360) 2023-08-13T21:53Z [---] followers, [----] engagements "@Pirateye2 You bring up a good point. Why is Covaxin sidelined A traditional vax thats economical proven safe and effective in recent USA trials with manufacturing ready to go. Government sidelines that giving the people no other option but mrna at $100+ a pop Its sus no doubt" [X Link](https://x.com/NattaCop/status/1690863234356785153) 2023-08-13T23:09Z [---] followers, [---] engagements "@AWAREOFSILENCE With news comes volume" [X Link](https://x.com/NattaCop/status/1697655467340861951) 2023-09-01T16:59Z [---] followers, [--] engagements "$ocgn The new Covid variants carry up to [--] mutations in their spike protein which will circumvent these new mRNA booster shots just like all the previous rounds. The mounting pressure on Gov to accelerate the development of next-generation vaccines is reaching an all-time high. Covid exhibits one of the highest mutation rates among all viruses. The most economically viable approach to combatting Covid is through a viral vector platform as demonstrated by years of collected data. Ocugen already possesses this platform and inhalation technology proven to be effective with real-world data. A" [X Link](https://x.com/NattaCop/status/1697685256177135832) 2023-09-01T18:58Z [---] followers, [----] engagements "$1.8 billion to purchase [--] million mRNA vaccines for children. $1.8 billion for these mRNA vaccines that wont stop transmission have rare but serious side effects and will cost a significant amount to store and transport all for a virus that children are hardly affected" [X Link](https://x.com/NattaCop/status/1699954321243402536) 2023-09-08T01:14Z [---] followers, [--] engagements "@RickABright @UN @ScienceUnga Nice cant wait Helping save lives while saving everyone billions at the same time thank you #100DaysMission" [X Link](https://x.com/NattaCop/status/1700037735309062446) 2023-09-08T06:45Z [----] followers, [---] engagements "@Chef_Enrico Not this time. Gov needs a genuine vaccine" [X Link](https://x.com/NattaCop/status/1700903573192847480) 2023-09-10T16:06Z [---] followers, [--] engagements "@ChefFrankfalcon @MoreFlax Because the world will recognize our vaccine as safe. Next gen funding is to fast track phase2b and up. They just need to know the vaccine is safe since the phase 2b+ will figure out the correct dosing for best efficacy. Our vaccine is Sealy Certified safe in a very large P3.🍻" [X Link](https://x.com/anyuser/status/1703460639744893265) 2023-09-17T17:27Z [--] followers, [---] engagements "$ocgn if youve been paying attention you would be very proud of Ocugens achievements and very excited about the news to come. 🍻" [X Link](https://x.com/NattaCop/status/1706768153630683286) 2023-09-26T20:30Z [---] followers, [----] engagements "$ocgn Us after Ocu500 funding gets announced" [X Link](https://x.com/NattaCop/status/1709392372109541505) 2023-10-04T02:17Z [----] followers, [----] engagements "$ocgn a glimpse of the future its a shining light big news on deck our stock takes flight. With funding secured our rocket ignites what fool misses out on such delights" [X Link](https://x.com/NattaCop/status/1710799677418098970) 2023-10-07T23:30Z [---] followers, [----] engagements "$dpls Neural Signals Inc.s technology stands out due to its remarkable longevity and fast/accurate processing of brain-to-speech data. By placing their implant deep in the cerebral cortex they benefit from strong signal strength. This strength in combination with a brain-to-speech algorithm derived from Kennedys own data enables Neural Signals to achieve near real time brain-to-speech processing which is significantly faster compared to existing market technologies. The key to their longevity lies in their neurotrophic electrode-tipped glass cones. With this approach the brain grows into the" [X Link](https://x.com/NattaCop/status/1711049316922732734) 2023-10-08T16:02Z [---] followers, [----] engagements "@TanyaWa21545395 $18 came and went quick would of been a silly time to sell anyways since we would of definitely flew way way higher with EUA. Next launch will be a lot less volatile since our floor will be made of💰imo. 🍻" [X Link](https://x.com/NattaCop/status/1711544185181053034) 2023-10-10T00:48Z [---] followers, [---] engagements "We truly possess the best of both worlds. Own the only two approved delivery systems currently being used today while owning the most cost effective and safe next gen vaccine platform. Our viral vector platform can carry/deliver a very wide range of messages from vaccines to gene therapies our vectors can carry the message and deliver it safely. Our platform doesnt require unstable messaging like Mrna and doesnt need any toxic adjuvants to trigger an immune response. Our vectors trigger a immune response the same way nature intended. Introduce a message to a vector place it in a chamber and" [X Link](https://x.com/anyuser/status/1711859582791016568) 2023-10-10T21:41Z [--] followers, [----] engagements "$ocgn We will be green on the weekly chart for the next year. The bears have absolutely nothing at all now. Sure people could of feared a RS or the need to dilute when they didn't know if funding was coming or not. Now we have a straight path to a multi-billion dollar market without having to spend a dime. 😂 Tell me ocgn is a bad investment and l'll know you're either a fool or you're lying lol. We will keep moving on up week after week there's just really no other place for us to go. 🍻" [X Link](https://x.com/NattaCop/status/1712031829149258005) 2023-10-11T09:06Z [---] followers, [----] engagements "$ocgn Only market ready drugs do head to heads. Head-to-head studies in the medical field are done on market-ready drugs and devices because these products have undergone extensive testing received regulatory approval and established known safety and efficacy profiles. This approach ensures ethical patient treatment provides practical comparisons with existing standards and offers reliable data for informed healthcare decisions. While innovation is crucial head-to-head studies with approved products are essential for advancing medical knowledge and treatment options within the current" [X Link](https://x.com/NattaCop/status/1715418970361385237) 2023-10-20T17:25Z [---] followers, [----] engagements "$ocgn Same bears who were saying it's to bad Ocugen owns Covaxin and not BB's nasal vaccine because that's the future of vaccines. Now act like Ocu500 is not even developed after Ocugen gained exclusive rights. "The study involving Ocugen's vaccine will be administered via both intranasal and inhaled routes and is designed to help answer an important question - does an inhaled COVID-19 vaccine provide greater immune response than the same vaccine administered through a nasal spray." They want you to believe Ocu500 is not even phase [--] ready. They want you to believe that the NIH is" [X Link](https://x.com/NattaCop/status/1716488957331157256) 2023-10-23T16:17Z [---] followers, [----] engagements "Profound existential questions such as Who are we and Why are we here may elude us as long as our consciousness remains intertwined within the fabric of our own unique space and time. Perhaps conscious enlightenment only comes once we achieve equilibrium with the cosmos liberating our conscious minds from the constraints of time and space until our conscious superposition collapses once again" [X Link](https://x.com/NattaCop/status/1731396715805278270) 2023-12-03T19:35Z [---] followers, [---] engagements "@ilikethestocks They had to submit their plan to gain compliance to Nasdaq Nasdaq accepted this plan and granted them another extension. I trust management and I trust Nasdaqs judgment. Ive seen this play out b4 when ocgns pipeline was just a fraction of what it is today im not worried💯" [X Link](https://x.com/NattaCop/status/1734325752257216989) 2023-12-11T21:34Z [---] followers, [---] engagements "Gov will use consortiums like RRPV/BIOMAPS as funding vessels for Project Next Gen. Gov wants long term pandemic Preparedness with the ability to respond within [---] days. Their plan is to give companies with the right products incentives like OTAs(other transactional agreements) to boost capabilities and maintain necessary production rates. Unlike traditional Gov funding OTAs are flexible give companies creative freedom and provide companies intellectual property rights ect. Think long term partnership where Gov provides guaranteed long term demand so companies will continue to develop the" [X Link](https://x.com/NattaCop/status/1736218610920722903) 2023-12-17T02:55Z [---] followers, [---] engagements "$ocgn Gov will use consortiums like RRPV/ BIOMAPS as funding vehicles for Project Next Gen. Gov wants long term pandemic Preparedness with the ability to respond within [---] days. Their plan to achieve this is to give companies who own the right products incentives like OTA's (other transactional agreements I've mentioned them b4 🤑) to boost capabilities and maintain necessary production rates. Unlike traditional Gov funding OTA's are flexible give companies creative freedom and provide companies intellectual property rights ect. Think long term partnership where Gov provides guaranteed long" [X Link](https://x.com/NattaCop/status/1736848005410771262) 2023-12-18T20:36Z [---] followers, [----] engagements "$ocgn Ocugen received alignment on key aspects of the Phase [--] study designincluding the study endpoint patient enrollment strategy and study duration of one year. The Phase [--] clinical trial will enroll a broader group of RP patients including patients with the most common RHO gene mutation based on OCU400s potentially gene-agnostic mechanism of action. 🔥" [X Link](https://x.com/anyuser/status/1737803078643208536) 2023-12-21T11:51Z [--] followers, [----] engagements "$ocgn Shout out to all the real Gs invested in the next major player in pharmaceuticals our road to $10b+ MC is underway. To all the day traders who spent these days spreading fud on a small cap bio set to make a significant impact on lives well heres to hoping youll figure it out one day. Cheers to the journey to come 🍻" [X Link](https://x.com/NattaCop/status/1739786005824286935) 2023-12-26T23:11Z [---] followers, [----] engagements "You wont be alone fam. I secured acreage back when our pipeline was just a fraction of what it is today. Many bios claim to be developing market-disrupting products but only a small percentage actually prove them a reality. This is what makes investing in small cap bios so risky. So many horses to bet on but only one becomes industrys standard. Choose wisely and you could own a piece of a company who holds exclusive long term rights to a market worth billions. Ocugens entire pipeline crafted through years of hard work is now proving itself to be the future industry standard. Early backers" [X Link](https://x.com/anyuser/status/1739835942276665586) 2023-12-27T02:29Z [--] followers, [---] engagements "@AWAREOFSILENCE Happy new year fam Hope the 🐻s like death metal" [X Link](https://x.com/NattaCop/status/1741194122608927054) 2023-12-30T20:26Z [---] followers, [---] engagements "$ocgn you may be wondering what Ocugen is all about why we are up how much higher can we go is a drop coming or is there more news on the way Well I made a vid about all that. From Gov funding multiple drugs with fast tracked phase 3s one of only [--] companies to receive RMAT designation for multiple products set to disrupt multibillion 💵 industries licensing deals partnerships Consortiums with OTA Gov funding going to members(Ocugen being a member) B&M Gates Foundation funding a pipeline that will continue to evolve and more is what Ocugen has on the table. Also the company is fundamentally" [X Link](https://x.com/NattaCop/status/1742144332763988397) 2024-01-02T11:22Z [---] followers, 14.4K engagements "@bsdyork Ive been adding lately but once compliance comes the party wont stop there. Imo any true investor here will win this stock has $10b+ MC written all over it. 🍻" [X Link](https://x.com/NattaCop/status/1742210641019171162) 2024-01-02T15:46Z [---] followers, [---] engagements "$ocgn If youre curious on how Ocu500s study will most likely pan out well McMasters did a study comparing our ChAd vectors with Cansinos Adenovirus vectors as an inhalation(pics/link below). NIH will now compare our inhalation vs Nasal delivery devices. I assume inhalation will outperform nasal and anything else but if Nasal shows good results too Barda/B&M may want it too for its ease of use qualities. 🍻" [X Link](https://x.com/NattaCop/status/1744804925270593758) 2024-01-09T19:34Z [---] followers, [----] engagements "$ocgn if youre worried then you havent done enough DD. Huge news is coming and no it isnt India funding our R&D facility lol. Think more in terms of Global Access Everywhere. Deja vu fam will drop a new vid tomorrow. 😉🚀🍻" [X Link](https://x.com/NattaCop/status/1746749922672873712) 2024-01-15T04:23Z [---] followers, [----] engagements "$ocgn just wanna be crystal clear about what the DD suggests and what I mean by Deja Vu. What I mean is we moon Q1 with major PR to comfortably gain compliance with a pipeline thatll only bring more news to come. 🍻" [X Link](https://x.com/NattaCop/status/1747906580002349085) 2024-01-18T08:59Z [---] followers, [----] engagements "$ocgn did you know that our Inhalation platform may require only [---] gallons of drug substance for the production of [---] million doses In the McMaster trials(pic below) our ChAd vectors outperformed Cansinos Adenoviruses offered maximum protection at an even smaller fraction of the dosage needed compared to intramuscular vaccinesa major selling point. This efficiency allows us to profit more while charging considerably less. Investing in our platform is a win-win for everyone. Our technology involves cells with a message mixed with water utilizing cutting-edge delivery tech to deliver it to" [X Link](https://x.com/anyuser/status/1750592097223348331) 2024-01-25T18:50Z [--] followers, [----] engagements "@bsdyork Before compliance deadline 💯 🚀🌘" [X Link](https://x.com/NattaCop/status/1753935115733106909) 2024-02-04T00:14Z [---] followers, [---] engagements "$ocgn idk tough choice" [X Link](https://x.com/NattaCop/status/1756394759709663637) 2024-02-10T19:08Z [---] followers, [----] engagements "$ocgn An extended runway by bullish means like a premium DO/licensing deal/Gov funding/B&M funding ect will completely secure our future. This is when our whole pipelines value finally gets recognized by the market. We have multiple products starting phase [--] this year both RMAT designated fast tracked one of them being our cure to blindness and that trial has only a [--] year duration and will start anytime now (early this year). We also have Gov funding for vaccines expected to come funding that will go towards manufacturing for rapid preparedness and in forms like OTA's which are super" [X Link](https://x.com/NattaCop/status/1759808894564778105) 2024-02-20T05:15Z [---] followers, [----] engagements "Yes to partnerships no to a buyout. Ocugen is poised to become a major player in the pharmaceutical industry. Shankar didnt leave Big Pharma after successfully launching their most profitable product acquiring all these patent rights and establishing a robust pipeline and team just to sell it all away to Big Pharma right as were gearing up for commercialization. The company lacks incentives to sell out even at a substantial premium. Consider managements fixed-rate warrant structure which vests over years and doesnt expire for ten years. Most of these warrants being fixed at a higher price" [X Link](https://x.com/NattaCop/status/1760408734176874950) 2024-02-21T20:58Z [---] followers, [---] engagements "$ocgn If I shared what our actual SP should be based on Ocu400 revenue projections for US/EU alone I would come off as a crazy person. Once partnership provides the cash to secure our pipeline $18 would be considered a massive discount this is what the facts/math shows not hopes/dreams. Do a risk adjusted NPV on just our Ocu400 series If youre looking to blow your mind. Craziest thing this is just the beginning. Ocugens journey from a small cap pre rev Bio to Big Pharma has begun and this is the year the world takes notice. Own a piece before they do I certainly will 🍻🚀" [X Link](https://x.com/NattaCop/status/1769595135887921453) 2024-03-18T05:22Z [---] followers, [----] engagements "$ocgn Pharma USA event starting the 26th Big Pharma partnership for Ocu400 our gene agnostic therapy World Vaccine Congress starting April 2nd next generation inhalation & nasal vaccine for Operation Next Gen. with the events to come our news on deck overseas partners breakthrough products and the new members of our team like Connie Collingsworth one of the founders of the B&M Gates foundation. Ocugen is poised to have one hell of a year. [----] the year of global recognition. 🍻" [X Link](https://x.com/NattaCop/status/1772614661709705596) 2024-03-26T13:20Z [---] followers, [----] engagements "$ocgn congrats fam we did it" [X Link](https://x.com/NattaCop/status/1772740989381202189) 2024-03-26T21:42Z [---] followers, [----] engagements "Covid revealed our pandemic unpreparedness. Operation Warp Speed emphasized speed but lacked the science and transparency. While bad actors celebrated success while they got the f outta dodge were left with a mess and vulnerable. Grateful for voices like @RickABright who continue to fight the good fight no matter the cost. One of the few public health figures I trust who always put science/people first with a history to back that claim. As the world shifts focus on preparedness and response its nice knowing theres some voices of logic and reason at the table especially as a case of avian flu" [X Link](https://x.com/NattaCop/status/1776452678236938317) 2024-04-06T03:31Z [---] followers, [----] engagements "$ocgn will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference presented by Noble Capital Markets taking place from April [--] - [--]. 🍻🐂 https://ir.ocugen.com/news-releases/news-release-details/ocugen-participate-fireside-chat-emerging-growth-virtual/ https://ir.ocugen.com/news-releases/news-release-details/ocugen-participate-fireside-chat-emerging-growth-virtual/" [X Link](https://x.com/NattaCop/status/1778752309675298879) 2024-04-12T11:49Z [---] followers, [----] engagements "$ocgn RP affects nearly [--] in [-----] in [----] people worldwide. In regions like United Arab Emirates (UAE) Saudi Arabia Kuwait and others the disease is more prominent affecting nearly about two and half times of other countries like the US and Europe. Commercial rights to this region will not be cheap imo. 🍻" [X Link](https://x.com/NattaCop/status/1778761333309317128) 2024-04-12T12:25Z [---] followers, [----] engagements "@StocksNdCrypto @Mr_Yambone https://twitter.com/nattacop/status/1780749131570717104 @Dfwmb123 No these are not shares bought these are warrants awarded. They give her the right to buy those shares at $1.59. They become available in chunks over [--] years and expire after [--] years. 🍻 https://twitter.com/nattacop/status/1780749131570717104 @Dfwmb123 No these are not shares bought these are warrants awarded. They give her the right to buy those shares at $1.59. They become available in chunks over [--] years and expire after [--] years. 🍻" [X Link](https://x.com/NattaCop/status/1780779083942789262) 2024-04-18T02:03Z [---] followers, [---] engagements "No because she lead the phase 1/2 these shares are awarded to her for the stellar results she got. Results that just expanded our phase [--] to treat broad RP which increases the target market of Ocu400 by multitudes and big pharma cant really buy some rights to a drug without knowing the target market. These shares are not some perfectly timed scheme to get rich this is just literally the process and the natural order of things. Next in line should be finalizing the BP deal. 🍻" [X Link](https://x.com/NattaCop/status/1780785398081531974) 2024-04-18T02:28Z [---] followers, [--] engagements "$ocgn bulls here whove spent this last year accumulating are about to transform into whales. Market is prioritizing books over pipeline but our pipelines value is on the verge of recognition. Big Pharma is at an inflection point their bread and butter products face patent expiration. To persevere pharma giants are looking for new targets that give them a leg up before that patent cliff. Products like monoclonal antibodies is what saved pharmas top line back then. The inflection point now is emerging innovations in cell and gene therapies targeting oncology ophthalmology rare diseases and" [X Link](https://x.com/NattaCop/status/1784939350549299384) 2024-04-29T13:34Z [---] followers, [----] engagements "$ocgn Dont forget that near the end of June well be listed back on the Russel3000. Remember how tute ownership started to fall off a cliff when we got booted from Russel last June Well many tutes have rules for risk management where they only invest in Russel listed companys. So think about the major news we have lined up the timing of it all and the absolute FOMO it will bring as were listed back on the Russel while tutes are all fighting to secure their ownership. Imo theres a reason why Zhang the only insider who bought the lows and sold the all time highs the last time around decided to" [X Link](https://x.com/NattaCop/status/1788924260611932532) 2024-05-10T13:29Z [---] followers, [----] engagements "$ocgn Because of a partnership with big pharma. Think about the news that we have lined up. If we want ocu400(and more later) to hit the market globally as quickly as possible then partnering with a big pharma company with a global footprint already is the best way to do this. Big pharma will of course want to own some stock in Ocugen just like BB owned a small amount of Ocugen when we partnered with them for Covaxin just this will be bigger than that. If you look at Novartiss partnership with Roche their partnership came with Novartis owning around a 30% stake. Their partnership formed in" [X Link](https://x.com/NattaCop/status/1789398607487218159) 2024-05-11T20:54Z [---] followers, [----] engagements "$ocgn The Series C distribution on the 22nd will secure Ocugens current control (voting power) protecting it from potential large purchases by future partners which prior to Series C could have gained excessive voting power. Following this there will be a vote to increase authorized shares for the partnership. Then the company will announce the biggest news in its history: a partnership with a major pharmaceutical company granting Ocugen a global footprint for their revolutionary drug(s). Ocugen will transform from a speculative bet into a cash-strong biotech with a clear path to global" [X Link](https://x.com/NattaCop/status/1790725732454543835) 2024-05-15T12:47Z [---] followers, [----] engagements "No its just something that I follow and know will come on the last trading day of June. Many institutions wont touch a non Russel listed company as part of their risk management strategy. Its why you see institutional ownership explode after June [----] and why it plummeted after June [----]. Ive already seen this movie before its why Ive said deja vu for the last year. If youve enjoyed it thus far just wait till you see whats to come. Spoiler alert this sequel has a different and more bullish ending. 😉🍻" [X Link](https://x.com/NattaCop/status/1791967798819962972) 2024-05-18T23:03Z [---] followers, [---] engagements "$ocgn late this month/next month should be the time they 🌙 us. Shorts failed big time even had the perfect fud to pump. Bulls will be accumulating in the $1.5 range till 🚀 at least I will be. Life changing money coming soon 🍻 💰 🏦" [X Link](https://x.com/NattaCop/status/1800246613992165381) 2024-06-10T19:20Z [---] followers, [----] engagements "$ocgn only a few close to us no one doing it like us multi-billion dollar markets exclusively ours and billions in yearly revenue in our horizon. This is Ocugen soon to be the next big pharma. Like other big pharma companies like Pfizer Novartis GSK ect dividends and share buy backs are a likely outcome here. Buy hold help the world while helping your wallet. Only winners here. 🍻 #OCUGEN look what they think of us."Pivotal" only few companies even close to us https://t.co/WdVsNiBpZ0 #OCUGEN look what they think of us."Pivotal" only few companies even close to us https://t.co/WdVsNiBpZ0" [X Link](https://x.com/NattaCop/status/1803181930999132513) 2024-06-18T21:44Z [---] followers, [----] engagements "$ocgn Remember that one time when the director of NIAID who was also lead for the White House Covid Task Force insisted that mRNA vaccines were all we needed fast-tracked approvals based on trials done on eight mice while blocking any path to market for traditional vaccine options even ones that had Phase [--] data overseas Remember how mRNA is so unstable that Gov needed billions of taxpayer dollars to buy next-gen sub-zero freezers just to keep them from spoiling for a few months Remember how they shoved it down our throats telling us were lucky and privileged to have the government spend our" [X Link](https://x.com/NattaCop/status/1818553879770062963) 2024-07-31T07:46Z [---] followers, [----] engagements "$ocgn stock market had its worst July in a decade and bears still cant take us down even after an offering lmao. Theres no where for this stock to go but up from here. Major news is coming back to back including today where Ocugen will now bring in revenue from a product through early access. Cheers bulls today our road to be pharma starts and its gonna be one hell of a ride. 🍻 New song Bag Like That" [X Link](https://x.com/NattaCop/status/1820542875014492399) 2024-08-05T19:30Z [---] followers, [----] engagements "$ocgn big money has their eye on the next big pharma. Do you Blackrock $14.1m shares added haha LFG #WinnersWin" [X Link](https://x.com/NattaCop/status/1823500461149970436) 2024-08-13T23:22Z [----] followers, [----] engagements "@nirjovega Its not 13f typically reflect long positions and large institutions like BlackRock report only their long equity holdings in these reports. When they short they use different mechanisms or accounts that wont be reflected in a 13F filing. 🍻" [X Link](https://x.com/NattaCop/status/1823505175811952705) 2024-08-13T23:41Z [----] followers, [---] engagements "The American people deserve the truth. FDA do you remember Covaxin The traditional whole-virion vaccine that you forced to jump through every bureaucratic hoop while you were fast-tracking mRNA boosters based on trials conducted on just [--] mice You urged the company to seek approval through a U.S. BLA trial and they didspending over $100 million on a massive Phase [--] trial that yielded top-line data showing broad protection against all variants of concern. Yet despite this you never approved an alternative traditional vaccine option after they successfully navigated your obstacle course. Why" [X Link](https://x.com/anyuser/status/1826770960487514134) 2024-08-22T23:58Z [----] followers, 143.4K engagements "$ocgn LFG Our day is coming and Im so damn excited to finally see it come to fruition. Science and the good guys will prevail for the worlds sake they must 🔥" [X Link](https://x.com/NattaCop/status/1827027338233835942) 2024-08-23T16:57Z [----] followers, [----] engagements "Novartis a company with a Gene therapy that also treats RP targeting mutations that affect .5-1% of the total RP market brought in $45b in [----]. Their market cap is roughly 6x this at $262b. So if we assume the same 6x multiplier off $30b in rev off just one of our products(imo thats low considering our other gene therapy would be just around the corner to cure AMD would forecast a lot more yearly revenue) that would put us at a $180b MC or $625sp. Way the company is structured too incentivizes growth so with that much cash on hand dividends and buy backs are likely. Theyll probably forward" [X Link](https://x.com/NattaCop/status/1828540915356704998) 2024-08-27T21:11Z [----] followers, [---] engagements "@salvador_wolf @MoreFlax Just what I see coming based on a whole lot check my other commented above I mention some 🍻" [X Link](https://x.com/NattaCop/status/1828839441089343815) 2024-08-28T16:57Z [----] followers, [---] engagements "Its almost like some stocktwits bear trolled her like how they try to get investors to vote against a company and she actually just ran with it. Just what everyone needs right now especially investors here the biggest market crash with money pouring out of growth stocks and the most volatility the market would ever see constantly just in time for our big news too. Ffs 🤦♂ I get people having beef with trump sure dudes no saint and Im glad were seeing RFK instead of fauci this time around. With what Kamala is proposing though I truly dont care if trump banged your wife theres literally no" [X Link](https://x.com/NattaCop/status/1828936168865706321) 2024-08-28T23:22Z [----] followers, [---] engagements "Definitely not. The fundamental structure of a company is just as important as its management and products imo. That structure reveals executive incentives and shows the paths management is likely to take. How many times have we seen investors buy into a companys vision only to get burned because the structure incentivized decisions that didnt align with shareholder interests I see it all the time. For example when a CEO is getting a percentage of the float every year and then they announce a reverse split it doesnt surprise me. But Ocugens structure is an investors dream. Its built to" [X Link](https://x.com/NattaCop/status/1832586237850612074) 2024-09-08T01:06Z [----] followers, [---] engagements "(Part 2) Ocu200 is a fusion of two molecules widely recognized for their cancer-fighting properties. Studies show that Tumstatin halts the formation of blood vessels that supply tumors effectively starving cancer cells while Transferon boosts the bodys ability to recognize and destroy cancer cells. If Ocu200 demonstrates that the fusion of these two molecules does what these studies suggest the standalone molecules dothat it will have synergistic effects when combined with anti-VEGF drugs like Lucentisit wont just be a therapy for AMD. It would become a new tool for fighting a wide range of" [X Link](https://x.com/NattaCop/status/1834304112005186039) 2024-09-12T18:52Z [----] followers, [----] engagements "The answer is simply business. Were a pre rev bio holding many cards but limited funds. We needed to focus on what we felt had the greatest likelihood of success first before continuing with the rest. Lucky for us Ocu400s bet has yielded amazing results and govs handling Ocu500 R&D. Youre right though Ocu200 developments does suggest something imo that something is confidence in our abilities to fully develop it though. 🍻" [X Link](https://x.com/NattaCop/status/1834482930007376271) 2024-09-13T06:43Z [----] followers, [---] engagements "Im like why do you sound so familiar. The nonsense and aggressive tone over something so trivial and easy to look up. Screenshots of something chat gpt wrote portrayed as some source for your bs when the companys stated SEC filed and all the easy to google articles/interviews are everywhere going over every detail of the CMC issue and hold(was Covid btw our manufacturer pivoted to manufacturing vaccines). Then it hit me I remember who you are. Whats up Phil you absolute legend your style of ignorant stupidity is so unique that it reminded me of our last convo over a year ago before your" [X Link](https://x.com/NattaCop/status/1834584720862224406) 2024-09-13T13:27Z [----] followers, [---] engagements "Literally nothing this week is a historically bad week for the market and bears used it to short and bash the stock and retail panicking like some fundamental shift happened with the company. Nothings changed Shankar even mentioned theres lots of interest in Ocu410 and they plan to partner with big pharma for Ocu410 in Q1 before they go phase [--]. Shorts/institutions are taking advantage of retail load and hold with big money and youll win big launch at the latest q1 imo. 🍻" [X Link](https://x.com/NattaCop/status/1838673051413794945) 2024-09-24T20:13Z [----] followers, [---] engagements "Ah I see now. Youve got to dig deeper into how a company is fundamentally structured if you want to predict what management will do next. I think Ive seen you around for awhile I dont think youre a troll so Ill share some key insights and hope Im not just wasting time. I wasnt randomly guessing when I spent a whole year posting about how Ocugen will choose two [---] day extensions and hit compliance in Q1 this wasnt based on hopium. Take MULN as an example. I called that they would reverse split before they did the first one. Why would I think that Because the CEOs compensation is tied to a" [X Link](https://x.com/NattaCop/status/1838744727296106516) 2024-09-25T00:57Z [----] followers, [---] engagements "$ocgn Us early investors are taking a calculated risk on products projecting $4b+ in yearly revenue. If things go as planned then even the most modest valuations will yield us the bulk of growth near term. For example Eli Lilly brings in $45b a year in revenue with a market cap of $834b valued at 18.5x yearly revenue. This is on the higher side of the average (10x-20x) but not unreasonable some bios see 30x their yearly revenue if the market is extra bullish on their future. Say for whatever reason Ocugen only gets valued at 4.5x yearly revenue well that puts their market cap at $18.5b and SP" [X Link](https://x.com/NattaCop/status/1840440245546074533) 2024-09-29T17:15Z [----] followers, [----] engagements "$ocgn shocking who would have thunk it https://www.trialsitenews.com/a/breakthrough-emory-researchers-find-covid-19-mrna-vaccines-fail-to-prompt-long-term-antibodies-b210949b https://www.trialsitenews.com/a/breakthrough-emory-researchers-find-covid-19-mrna-vaccines-fail-to-prompt-long-term-antibodies-b210949b" [X Link](https://x.com/NattaCop/status/1840712730489376942) 2024-09-30T11:18Z [----] followers, [----] engagements "Today Im sharing my theory of everything. When Im not deep diving into stocks Im often lost in the mysteries of the cosmos. One of the most fascinating puzzles for me Quantum mechanics. After years of pondering I think I might be onto something. My theory challenges the core ideas of the quantum realm but Im not claiming proof experiments need to be done and Ive laid out how. Heres the kicker: a time-uncertainty principle. Time is fluid. Click the link to this rabbit hole if you dare🤓😉 https://mytheoryofeverything.tiiny.site https://mytheoryofeverything.tiiny.site" [X Link](https://x.com/NattaCop/status/1844897368317231431) 2024-10-12T00:26Z [----] followers, [----] engagements "$ocgn Time to fast track Ocu520" [X Link](https://x.com/NattaCop/status/1846534667245355091) 2024-10-16T12:52Z [----] followers, [----] engagements "$ocgn good Ocu410 data would imply a lot more than a potential cure for a disease effecting millions. It solidifies the deal Ocugen has to offer and a partnership that includes territorial rights for Ocu400 the next cure for RP and Ocu410 a potential cure for Geographic Atrophy(GA) thats phase three ready is a deal worth well over a billion dollars. A phase [--] gene therapy for GA sold for $1.5b in [----] but failed its phase [--] September [----]. 🔜💸 🏦👽" [X Link](https://x.com/NattaCop/status/1847085174322090151) 2024-10-18T01:19Z [----] followers, [----] engagements "You bring up a good point but theres grey areas on whats considered material and we fall directly in this area. For early phase trials like Phase 1s companies have flexibility regarding the timing of the trials progression. Also Ocugen will know how their drug is progressing well before the trial formally concludes. For example Shankar mentions that Ocu410s safety interim results are coming soon and how theres global interest in them. Companies are not required to publicly disclose good interim safety reports within [--] days this is not counted as material information and is considered part of" [X Link](https://x.com/NattaCop/status/1847411130727342252) 2024-10-18T22:55Z [----] followers, [---] engagements "Early on during the pandemic US sent their top team of scientists to Wuhan to figure out its origins. Anyways after scientists spent a week there I just happened to be listening to NPR and heard there report live. They said it came from a lab and NPR asked them how sure and they responded 99.8% sure and they cut the broadcast immediately. Following this was nonstop media coverage about the lab leak conspiracy and how it held no merit even though the report is on govs website and the conspiracy came from the top experts. I will never forget it was truly shocking to hear first hand." [X Link](https://x.com/NattaCop/status/1848446354479321332) 2024-10-21T19:28Z [----] followers, [---] engagements "$ocgn Know what you own because the current share price doesnt even come close to reflecting it. Retail isnt buying millions of shares daily smart retail has bought and is holding or continues to buy paycheck to paycheck and holding. Case in point: todays short volume was 1.84M shares making up 73% of the total volume and yet we only dropped 0.9%. 😂 So does 73% short volume mean that institutions are bearish on Ocugen Out of the [---] institutions that own Ocugen [---] of them are long only [--] have a long position with a short hedge and ZERO are short only. The bearishness here is just a fugazi." [X Link](https://x.com/NattaCop/status/1848933928037704015) 2024-10-23T03:46Z [----] followers, [----] engagements "$ocgn Been here since the company went public telling everyone not to fear a reverse split. My take faced a lot of criticism but I knew one would never happen given the fundamental structure. While others pushed fear I advised everyone to load up for the compliance push explaining how Q1 was the most likely time for it with nothing but big news set to follow. From $0.30 to over $1 we went achieving compliance late Q1. Now here I am again urging you all to prepare for the massive catalyst on the horizon. The coming week marks a major inflection point for Ocugen with Ocu410s Phase 1/2 data" [X Link](https://x.com/NattaCop/status/1854674921437512186) 2024-11-07T23:58Z [----] followers, [----] engagements "@JJRich59 They know when to play their cards and 🎯 the [--] tutes short on ocgn do it as a hedge with shares to cover/go long. Imo price will rise a good bit before management is awarded their vested fixed rate warrant compensation then perfect time for big news PR & rip retail shorts 😂" [X Link](https://x.com/NattaCop/status/1854743491231764815) 2024-11-08T04:31Z [---] followers, [---] engagements "$ocgn oh am I excited about this clinical showcase next week. This data has to be really good showcasing the efficacy results with the trial participants there in the flesh. Big Pharma has sought a Geographic atrophy drug for decades. Will become an instant blockbuster with a market in the millions. Bask in the sp absurdity do as big money is doing and load up on the next Big Pharma company before anyone realizes what they have accomplished and own. This is beyond an obvious win fam capitalize 🐂" [X Link](https://x.com/NattaCop/status/1855018087885815937) 2024-11-08T22:42Z [----] followers, [----] engagements "$ocgn Great to see the @US_FDA s Guidance for Industry prioritizing gene therapy acceleration for rare diseases and unmet medical needs. [--] in [--] people reading this will face a condition without approved treatments. With guidelines like these gene-agnostic drugs full potential can be unlocked bringing hope back to millions. with a quicker less risky path to market companies can finally explore all possible markets for a drug instead of just the most profitable ones. #OCUGEN #OCU400 #OCU410 #ICU410ST .really interesting stuff it is about [--] pages but I post the most interesting ones in my" [X Link](https://x.com/NattaCop/status/1855719359907528843) 2024-11-10T21:09Z [----] followers, [----] engagements "@RobertKennedyJr Absolutely just look at the way Fauci handles this question. From media pumping agendas to government officials selling us products they get kickbacks from with sales funded by taxpayer dollars. The propaganda is heavy and beyond obvious. Get them snakes RFK good luck" [X Link](https://x.com/NattaCop/status/1855791996448981192) 2024-11-11T01:57Z [----] followers, [----] engagements "$ocgn stellar data and showcase inbound Lesgo 🐂" [X Link](https://x.com/NattaCop/status/1856067697685213193) 2024-11-11T20:13Z [----] followers, [----] engagements "we spent at LEAST $15m the last two years to protect this POS while @RobertKennedyJr was denied gov security [--] times as a presidential candidate. Fauci a private citizen who made millions off mRNA kickbacks from sales funded by taxpayers is still freeloading off us. 🤦♂" [X Link](https://x.com/NattaCop/status/1856126331341156818) 2024-11-12T00:06Z [----] followers, [----] engagements "$ocgn absolutely incredible couldnt ask for better results. This data represents hope for millions around the world. 🤯 Big Pharma look out 😜 🚀" [X Link](https://x.com/NattaCop/status/1856400317094715645) 2024-11-12T18:15Z [----] followers, [----] engagements "@Jzy8902 Not even counting Stargardt NeoCart and Next Gen vaccines too. 🤯💸 🏦" [X Link](https://x.com/NattaCop/status/1856699271778889735) 2024-11-13T14:02Z [----] followers, [---] engagements "$ocgn just a friendly reminder to know what you own because the people below sure as shit know what their buying. 😉🍻" [X Link](https://x.com/NattaCop/status/1856851220843172033) 2024-11-14T00:06Z [----] followers, [----] engagements "$ocgn its that easy. 🐂" [X Link](https://x.com/NattaCop/status/1857122045294948445) 2024-11-14T18:02Z [----] followers, [----] engagements "$ocgn nice 😎 Dr. Huma Qamar Chief Medical Officer at Ocugen shared her insights on managing complex gene therapy trials to ensure quality and consistency in patient care with @ClinicalLeader1 and @_CellandGene To read the full article click here: https://t.co/6zcBLhTocC Dr. Huma Qamar Chief Medical Officer at Ocugen shared her insights on managing complex gene therapy trials to ensure quality and consistency in patient care with @ClinicalLeader1 and @_CellandGene To read the full article click here: https://t.co/6zcBLhTocC" [X Link](https://x.com/NattaCop/status/1857861265689108638) 2024-11-16T19:00Z [----] followers, [----] engagements "@crisis_parade @DaniBeckman Me 😎" [X Link](https://x.com/NattaCop/status/1857870451734905259) 2024-11-16T19:36Z [----] followers, [---] engagements "@crisis_parade @DaniBeckman Thanks not on Spotify to my knowledge I made a playlist on SoundCloud though that has most of my songs. 🍻 https://on.soundcloud.com/dmJ2VWjiBXRUDLQZA https://on.soundcloud.com/dmJ2VWjiBXRUDLQZA" [X Link](https://x.com/NattaCop/status/1857880006732689853) 2024-11-16T20:14Z [----] followers, [--] engagements "$ocgn say whaaat 😲🤯" [X Link](https://x.com/NattaCop/status/1858509142559977611) 2024-11-18T13:54Z [----] followers, [----] engagements "$ocgn 💰🐂🐂🐂 https://ir.ocugen.com/news-releases/news-release-details/ocugen-announces-compelling-preliminary-data-ocu410-single-dose/ https://ir.ocugen.com/news-releases/news-release-details/ocugen-announces-compelling-preliminary-data-ocu410-single-dose/" [X Link](https://x.com/NattaCop/status/1858850123218121144) 2024-11-19T12:29Z [---] followers, [----] engagements "$ocgn Wow Listening to the patients just made my day 🥲 ❤ Theres no better feeling than making money while changing the world for the better. These drugs just revolutionized the gene therapy industry. A one shot solution to countless diseases bringing hope back to millions. Were at the forefront to a new age in healthcare. What an incredible time to be invested. 🍻" [X Link](https://x.com/NattaCop/status/1859333833306644885) 2024-11-20T20:31Z [---] followers, [----] engagements "$ocgn got friends in high places" [X Link](https://x.com/NattaCop/status/1859415336216560075) 2024-11-21T01:55Z [----] followers, [----] engagements "$ocgn soon to be leaders in the gene therapy industry. 🐂" [X Link](https://x.com/NattaCop/status/1861400748208398448) 2024-11-26T13:24Z [---] followers, [----] engagements "$ocgn were at [---] institutional owners now lol. To the retail getting robbed before our rise I tried to warn you. 😂 💀 To the ones who know what you own exciting times ahead. 🍻" [X Link](https://x.com/NattaCop/status/1861866993814847868) 2024-11-27T20:17Z [---] followers, [----] engagements "$ocgn comprehensive value analysis of a BP partnership catalyst. You know what I expect but what value do you see coming to Ocugen near term(1 year) to long term(2-5 years)" [X Link](https://x.com/NattaCop/status/1865941965285863670) 2024-12-09T02:10Z [---] followers, [----] engagements "$ocgn 🔥👏 https://finance.yahoo.com/news/data-safety-monitoring-board-reviews-113800039.html https://finance.yahoo.com/news/data-safety-monitoring-board-reviews-113800039.html" [X Link](https://x.com/NattaCop/status/1869731488226492688) 2024-12-19T13:08Z [---] followers, [----] engagements "@RobertKennedyJr @MartyMakary @elonmusk @realDonaldTrump You guys must put a stop to this madness. Our health agencies scientists and Big Pharma are laundering billions of taxpayer dollars. They spend enormous sums on a single platform that will never eradicate infectious diseases while actively blocking market access for platforms that could. Theyre selling the public misleading data and false hope lining their pockets as billions are wasted. This platform only mimics a small part of viruses famously studied for their high mutation rates. Its efficacy is short lived and plummets when" [X Link](https://x.com/NattaCop/status/1871320725891744101) 2024-12-23T22:23Z [---] followers, [----] engagements "@amldean19 @RobertKennedyJr @MartyMakary @elonmusk @realDonaldTrump 😂 🙏" [X Link](https://x.com/NattaCop/status/1871364575360377016) 2024-12-24T01:17Z [---] followers, [--] engagements "$ocgn hint smart money buys before approval. Youre welcome. 😉🍻" [X Link](https://x.com/NattaCop/status/1874708840517886263) 2025-01-02T06:46Z [---] followers, [----] engagements "$ocgn key things to note. Ocu410s phase [--] has [--] participants just 1/5 the size of typical gene therapy trials for geographic atrophy (GA) . 255-365 participants). This suggests the FDA has significant confidence in OCU410s safety and its mechanism of action in reducing lesion growth in GA patients based on promising Phase [--] results. Phase [--] dosing is expected to complete early this year followed by 9-12 months of efficacy updates measuring lesion growth and visual acuity improvements. Ocugen has been working closely with the FDA to potentially structure this Phase [--] trial as a Pivotal trial." [X Link](https://x.com/NattaCop/status/1876417161369162200) 2025-01-06T23:54Z [---] followers, [----] engagements "$ocgn look at the trial results below. While other gene therapies targeting single mutations are being bought for billions we own a drug that corrects over [---] mutations. For the first time in history humanity has unlocked the master regulators of genetics allowing us to cure countless diseases with a single breakthrough. You move methodically after unlocking the new frontier of Gene Therapy patients pays ten fold here. 🍻" [X Link](https://x.com/NattaCop/status/1879540797865070828) 2025-01-15T14:47Z [---] followers, [----] engagements "$ocgn I think LFG and its about damn time. @NIH @BARDA @Ocugen The data is clear: the Viral Vector platform is designed to outperform others for pandemic preparedness especially as a mucosal vaccine against respiratory viruses. The few hurdles listed associated with Viral Vectors are overcome using ChAd vectors. This technology has already proven itself overseas with millions of doses administered as a mucosal vaccine. Providing long lasting protection while only using a fraction of the drug substance compared to intramuscular vaccines. Americans are fortunate that a U.S. based company owns" [X Link](https://x.com/NattaCop/status/1880385924120605057) 2025-01-17T22:45Z [---] followers, [----] engagements "$ocgn Psst hey you yes you follow me I wanna show you something. See the list below Its a list of every expedited approval that happened in [----]. Impressive Sure. But heres the fun part I went ahead and analyzed each one and compared it to Ocu400. What I found is simple: OCU400 doesnt just stack up against these its in a league of its own. Efficacy safety unmet needs you name it OCU400 dominates the board. These other drugs earned early FDA approval but they dont even come close to what Ocugen has delivered. 100% efficacy mutation agnostic design zero serious adverse events and the cure to" [X Link](https://x.com/NattaCop/status/1880844132886999403) 2025-01-19T05:06Z [---] followers, [----] engagements "Somewhat cash strong with runway to [----] and lines to get debt financing. Management ownership is all tied up in vested fixed rate warrants and company continues to expand their heavy hitting pipeline so well be looking at partnerships for Ocu400/410 not buyout. Vid shows Shankar talking about when theyll look at the partnership offers note they received non dilutive funding after this conference. Imo even if Ocugen has all the financing they need to go commercial alone well still see partnership happen likely with a company who has a global infrastructure footprint like Novartis. Takes time" [X Link](https://x.com/NattaCop/status/1881115706630299773) 2025-01-19T23:05Z [---] followers, [---] engagements "$ocgn it will be interesting to see what happens after the purge of incentivized corruption and the scientific playing field is leveled. Ocugen truly owns the best platform to prepare for infectious diseases especially respiratory ones with our advanced delivery systems. Shankar was one of the creators and lead the most successful global vaccine launches in history which gave Pfizer their number [--] most lucrative cash cow of all time. No one in this field has a more proven track record than him. With an even playing field the competition is miles behind. The innovations we bring will" [X Link](https://x.com/NattaCop/status/1884300302750474268) 2025-01-28T17:59Z [---] followers, [----] engagements "$ocgn Ocufam our time is finally coming. Why would Ocugen clear its debt and free up patent rights patents that had to be unrestricted for any partnership Which company just said theyd be reviewing all partnership agreements in Q1 Yup 🍻" [X Link](https://x.com/NattaCop/status/1885478282445152347) 2025-02-01T00:00Z [---] followers, [----] engagements "@catalyst_i Idk may be worth the look. I remember thinking the same with Bluebird Inc after approval for sickle cell. Turns out another drug Casgevy by Vertex Pharmaceuticals was approved same day and priced $1m cheaper($2m) than Bluebirds($3m). Vertex Casgevy sales beat expectations. 🍻" [X Link](https://x.com/NattaCop/status/1887510600202527084) 2025-02-06T14:36Z [---] followers, [--] engagements "$ocgn The real reason for Ocugens incredible discount after multiple trial results showing they possess the cure for blindness Retail doesnt comprehend it. The vast majority of retail money moving daily comes from day traders chasing hype trying to make a quick buck. Ocugen doesnt appeal to that kind of money pre revenue so no ER to pump R&D cash burn and products that only real investors care about. Big money is buying for the substance they hold control of our day to day SP hence why we see over 70% of daily volume trading through dark pools. They own the price action until news drops that" [X Link](https://x.com/NattaCop/status/1890460203172405606) 2025-02-14T17:56Z [---] followers, [----] engagements "$ocgn If you're investing do it for the catalysts not the day to day stock price. This is an extremely undervalued biotech with a pipeline that justifies a valuation closer to $10 billion than $100m. Management's incentives are aligned with shareholders here with most of their ownership tied to vesting fixed rate warrants. For example the majority of the CEO's ownership consists of warrants(right to buy shares at a later date) with a fixed(at a fixed price) exercise price of $1.25 which won't fully vest(become available) for another two years. So management incentives are focused on building" [X Link](https://x.com/NattaCop/status/1894019872369381625) 2025-02-24T13:41Z [---] followers, [----] engagements "$ocgn this is huge 🔥 https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-announces-fda-alignment-phase-23-pivotal-confirmatory https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-announces-fda-alignment-phase-23-pivotal-confirmatory" [X Link](https://x.com/NattaCop/status/1895113079819731253) 2025-02-27T14:05Z [---] followers, [----] engagements "$ocgn Ocu410ST [--] subjects [--] of whom will receive Ocu410ST One year data will be utilized for the BLA filing. 💥 🏦 💸 💸 🐂 $ocgn even though most of the market hasnt the faintest clue what a pivotal trial means I cant stop thinking about another product coming to market after a trial with just one year end points and needed to share it. Blockbuster after blockbuster. 🍻 https://t.co/wtYMWN6EsM $ocgn even though most of the market hasnt the faintest clue what a pivotal trial means I cant stop thinking about another product coming to market after a trial with just one year end points and" [X Link](https://x.com/NattaCop/status/1895119404473696280) 2025-02-27T14:30Z [---] followers, [----] engagements "$ocgn Ocugen filed a patent for a Multicistronic vaccine on February 13th. Multicistronic meaning the vaccine encodes at least two different antigens (influenza and COVID-19) aka Ocu520 our two in one Covid+flu vaccine. Now ask yourself why is Ocugen expanding their next Gen vaccine platform when govs in the middle of testing just their Covid vaccine Hint hint. 🍻" [X Link](https://x.com/NattaCop/status/1895206146061017264) 2025-02-27T20:15Z [---] followers, [----] engagements "$ocgn first partnership then pipeline explosion acquisitions and global expansion. We'll see Ocugen at all systems go towards their journey to becoming one of the giants in pharmaceuticals. Then revenue and insane profit margins think Novartis with extra billions in cash on hand each quarter. This is the start of a global takeover priced at $189m lol. No 🧠er💥🚀" [X Link](https://x.com/NattaCop/status/1896407960676626930) 2025-03-03T03:51Z [----] followers, [----] engagements "Novartis owns Luxturna the first gene therapy approved for RP which fixes one mutation responsible for 0.5%-1.5% of RP patients. Ocu400 is gene agnostic and will take over 50% of the market. Novartis also bought a Phase [--] gene therapy for GA for $1.7B but it failed Phase [--] and a week later Ocugen started dosing Ocu410 for Phase [--]. Novartis also sold their entire stake in Roche and is in the market for new drugs and partnerships. Ocugen already has its own cGMP manufacturing in the US while Novartis has extensive infrastructure in regions heavily impacted by inherited eye disease like MENA" [X Link](https://x.com/NattaCop/status/1896539662979825830) 2025-03-03T12:34Z [---] followers, [---] engagements "$ocgn same cycle same noise same outcome. Load the boat. 🍻" [X Link](https://x.com/NattaCop/status/1897472364323193113) 2025-03-06T02:20Z [---] followers, [----] engagements "@BrauneArno Yeah but still Novartis is a much more likely pick to partner for Ocu400/410 imo 😉 🍻" [X Link](https://x.com/NattaCop/status/1901769645885153307) 2025-03-17T22:56Z [----] followers, [---] engagements "$ocgn getting spicy over here 🐂" [X Link](https://x.com/NattaCop/status/1903076884390297633) 2025-03-21T13:31Z [----] followers, [----] engagements "$ocgn is the highest ranking pure biotech on this highest off exchange [--] day trading volume list. First we saw heavy short interest Then dark pool volume surge Next cost to borrow rate spiked Now the price is steadily rising without any insane volume or retail FOMO To me it looks like big players are accumulating anticipating a catalyst. They buy off exchange to avoid spiking the SP but this also pulls shares out of circulation. Less shares circulating means borrow fees go up which in turn puts pressure on the price to rise. Big PR is on our horizon imo. 🍻" [X Link](https://x.com/NattaCop/status/1904867370327564560) 2025-03-26T12:05Z [----] followers, [----] engagements "$ocgn Since the dawn of man vision loss in RP Stargardt LCA and dry AMD was inevitable. Once these diseases took hold a patients only option was to wait and watch as the light faded to black. But Ocugen said f*ck that reality and now for the first time in human history the future shines bright for millions around the world. Ocugen just added more updated data to their ever growing list of banging trial results. Data showing that treated eyes in the OCU410 dry AMD trial didnt just stabilize they gained nearly [--] lines (23 letters) of vision compared to the untreated eye. Thats no fluke. Thats" [X Link](https://x.com/NattaCop/status/1908301238560780747) 2025-04-04T23:30Z [----] followers, [----] engagements "$ocgn is the most discounted biotech on the market 💯 and heres why. In [----] investments in cell and gene therapy surged to $15.2 billion a [--] percent jump from the year before. But if you looked at Ocugen alone youd never guess it. The market at large doesnt grasp the complexity behind these next gen therapies. Were talking about correcting specific gene mutations to treat small subsets of patients. Thats a whole lot of variables for retail. And lets be real most people arent nerds like me 🤓. They dont have the time to look at the science and figure out what really separates one therapy" [X Link](https://x.com/NattaCop/status/1909601772739625435) 2025-04-08T13:38Z [----] followers, [----] engagements "Novartis has spent billions trying to carve out a foothold in the retinal gene therapy space capturing just 0.5% to 1.5% of the RP market with Luxturna and attempting to enter the massive GA market through GT005. Theyve also invested heavily in building out global infrastructure particularly in regions like the Middle East where inherited diseases are most prevalent. Ocugens drug OCU400 is designed to treat the majority if not all of the RP/LCA market. And their GA drug OCU410 began dosing for its Phase [--] trial just one week after Novartis announced it was discontinuing development of GT005" [X Link](https://x.com/NattaCop/status/1911210991880421443) 2025-04-13T00:13Z [----] followers, [--] engagements "$ocgn why buy Ocugen You gonna wish you did. 🍻 💸 🏦 🐂" [X Link](https://x.com/NattaCop/status/1929533560865853667) 2025-06-02T13:40Z [----] followers, [----] engagements "$ocgn this also includes a supply agreement "Ocugen will manufacture commercial supply of OCU400 under terms of a supply agreement.". That means Ocugen earns revenue from two streams: 25% royalty on net sales (huge by industry standards). Profit from manufacturing and supplying the product (likely adds 30-50% margin). $11M in upfront and near-term payments $1M for every $15M in net sales up to $150M+ in the first [--] years. So this isn't just a royalty stream it's: Guaranteed near term cash a built in reward system as Korean partner scales sales Control over manufacturing which keeps quality" [X Link](https://x.com/NattaCop/status/1930622788970414295) 2025-06-05T13:48Z [----] followers, [----] engagements "The $200 trillion is not liquid thats the gross national household net worth estimate. Talking private property homes retirement accounts stock holdings family businesses land art and not government owned. What is the suggestion here nationalizing private wealth My god were all cooked fam. Theyd rather come up with some scam than even attempt to balance the budget. Sovereign Wealth Funds only work with surpluses. You invest the excess revenue to generate returns or in this case pay off debt. The problem is we dont have a surplus. We have a $1.7T deficit and were borrowing just to pay the" [X Link](https://x.com/NattaCop/status/1931172663113994355) 2025-06-07T02:13Z [----] followers, 32.7K engagements "$ocgn you ever watch a stock go from spare change to double digits then triple Keep your eyes on Ocugen over the next [--] years youll see. The next big pharma is making its debut. 🍻 https://www.globenewswire.com/news-release/2025/06/11/3097456/0/en/Ocugen-To-Present-at-BIO-International-Convention-2025.html https://www.globenewswire.com/news-release/2025/06/11/3097456/0/en/Ocugen-To-Present-at-BIO-International-Convention-2025.html" [X Link](https://x.com/NattaCop/status/1932814692281692353) 2025-06-11T14:58Z [----] followers, [----] engagements "@BAMBossie81 Yes and I love the idea spin offs are a great way to see value from a product thats overlooked by the market. It also acts like a buffer from negatives that may come like big R&D costs and lower sales. Ocugen can see the value Neo deserves without the risks to their books" [X Link](https://x.com/NattaCop/status/1935488937881125242) 2025-06-19T00:04Z [----] followers, [---] engagements "@MoreFlax Ocu200 is a tumortargeting fusion protein (tumstatin + transferrin). Imo that news has always been coming but now Idk 🤷♂ could also be a typo 😆" [X Link](https://x.com/NattaCop/status/1935910360953020926) 2025-06-20T03:59Z [----] followers, [---] engagements "$ocgn When the merged company lists under a new ticker nothing changes for Ocugen holders we still own 90% of it. The new ticker just represents the public float (the other 1015%). If you already hold Ocugen you already own most of the new company. The easiest way to think about it is: Ocugen now owns a new asset. So if CARM trades at a $1B valuation Ocugen holds 8090% of that meaning weve got an $800900M asset sitting on our books. @NattaCop what happens when they list the new ticker for the merged company @NattaCop what happens when they list the new ticker for the merged company" [X Link](https://x.com/NattaCop/status/1937170538247737488) 2025-06-23T15:27Z [----] followers, [----] engagements "$ocgn Guys this is 100% a good deal a spin off is clever but isnt anything crazy or super hard to comprehend. The only way this wouldnt be a good deal is if you think Ocugens SP had NeoCart value significantly baked into its SP already and losing that 10% will hurt out bottom line. Fact is NeoCart was extremely overlooked by the market and our SP didnt reflect the value at all. Now this neglected asset will receive its true value and Ocugen gets to reap the benefits by having that now valuable traceable asset on our books and an early source of manufacturing revenue. If you wanted to fund" [X Link](https://x.com/NattaCop/status/1937191825942675793) 2025-06-23T16:51Z [----] followers, [----] engagements "Hence why I mentioned [--] to [--] percent. The [--] percent figure is before the funding. After the [--] million raise it drops slightly but that dilution covers the entire Phase [--] push without touching Ocugens balance sheet. We still own the majority control manufacturing and hold an asset that can grow independently while reflecting directly as value on our books. Thats the entire point. Risk is offloaded upside is kept" [X Link](https://x.com/NattaCop/status/1937237214657937646) 2025-06-23T19:51Z [----] followers, [---] engagements "Ive followed this product for over [--] years and I believe the value goes well beyond that. The upcoming trial is structured for approval. The last one failed due to one outlier group extremely thin patients with the smallest micro lesions. That group has been removed from the new Phase [--]. The market is massive and NeoCart with RMAT status and set for early access is positioned to become the new standard of care. The data speaks for itself. 🥂" [X Link](https://x.com/NattaCop/status/1937248646027943955) 2025-06-23T20:37Z [----] followers, [---] engagements "The [-----] percent ownership figure is based on a conservative $110 million valuation for Ocugens NeoCart asset. But that number only holds if the $20 million being raised is priced at that same valuation. In reality the final ownership percentages will depend on how the market values the new company when it lists. If demand is strong and the market values NeoCart and the merged entity above $110 million then investors putting in $20 million will receive a smaller percentage of the company and Ocugens ownership will end up higher than [-----] percent. At the end of the day the market has the" [X Link](https://x.com/NattaCop/status/1937262897903862237) 2025-06-23T21:34Z [----] followers, [---] engagements "Theres zero dilution of Ocgn shares from this merger. Ocugen didnt issue new stock it spun out OrthoCellix retained majority ownership of a new public company without burning any cash. If youre saying thats dilution you dont understand the deal. Show grok if you can the filing itself or screenshots then ask it. Or just read the filing yourself it really isnt too complicated. 🍻 https://www.streetinsider.com/dr/news.phpid=24962186 https://www.streetinsider.com/dr/news.phpid=24962186" [X Link](https://x.com/NattaCop/status/1937267854677803175) 2025-06-23T21:53Z [----] followers, [--] engagements "No it doesnt you tagged grok under a post with the most dog water take Ive ever seen. @grok analyze this link people are claiming that Ocugen shareholders are getting their shares diluted through this deal but theyre clearly confused. Explain why this deal doesnt dilute Ocugen shareholders and why its a bullish deal for Ocugen shareholders. https://www.streetinsider.com/dr/news.phpid=24962186 https://www.streetinsider.com/dr/news.phpid=24962186" [X Link](https://x.com/NattaCop/status/1937289731706093620) 2025-06-23T23:20Z [----] followers, [--] engagements "@amldean19 @BAMBossie81 🎯 Fact nobody ever gives this much of a dog water take about a filing with this much conviction whos genuinely just confused. This guy swing trades and posts solely to manipulate people based on his trades" [X Link](https://x.com/NattaCop/status/1937292410964611463) 2025-06-23T23:31Z [----] followers, [---] engagements "$ocgn NeoCart is the perfect candidate for government funding. Military accelerates joint degeneration especially the knees. VA spends billions annually treating this damage. Knee injuries are among the top service connected disabilities for veterans. Neocart would save them billions of dollars since NeoCart cartilage implant is designed to regenerate making it a curative treatment that would drastically reduce future surgery rates and long term disability claims. The numbers dont lie. There are existing government initiatives under ARPA-H BARDA and MTEC focused on regenerative medicine and" [X Link](https://x.com/NattaCop/status/1937937065569882275) 2025-06-25T18:12Z [----] followers, [----] engagements "$ocgn little birdie says" [X Link](https://x.com/NattaCop/status/1939801539910254987) 2025-06-30T21:41Z [----] followers, [----] engagements "$ocgn https://ir.ocugen.com/node/13931/html https://ir.ocugen.com/node/13931/html" [X Link](https://x.com/NattaCop/status/1940140327056167121) 2025-07-01T20:07Z [----] followers, [----] engagements "$ocgn many are confused saying didnt we go [--] consecutive days above $1. Youre not crazy we did stay above $1 for what usually is required by NASDAQ. This is not a SEC rule though its not black and white like that. NASDAQs exchange their rules and their discretion. Ive seen NASDAQ grant us compliance with far less bullish news and closer to $1 closing days. This time was they wanted a little more for whatever reason. Important thing is we were granted the [---] day extension and have a mountain of good news on the way. This is not a problem for us we will be just fine. 💯 🍻" [X Link](https://x.com/NattaCop/status/1940164500554228056) 2025-07-01T21:43Z [----] followers, [----] engagements "$ocgn Inside the new spending bill is something called the Orphan Cures Act and it changes everything. Ocugens modifier corrects [---] mutations. These mutations dont just cause RP/LCA those are just the two biggest markets. In reality there are over [---] inherited retinal diseases in the U.S. with 5000+ patients tied to those mutations that Ocugens modifier platform could treat in the same exact way. Altogether it could potentially address 200+ inherited retinal diseases. Before this bill government policy actually punished companies for expanding into more than one rare disease. Doing so" [X Link](https://x.com/NattaCop/status/1940313122272665851) 2025-07-02T07:34Z [----] followers, [----] engagements "$ocgn Spend billions now to save hundreds of billions from being burnt yearly later. 🍻 $ocgn Inside the new spending bill is something called the Orphan Cures Act and it changes everything. Ocugens modifier corrects [---] mutations. These mutations dont just cause RP/LCA those are just the two biggest markets. In reality there are over [---] inherited retinal https://t.co/YZHLu7Xfv5 $ocgn Inside the new spending bill is something called the Orphan Cures Act and it changes everything. Ocugens modifier corrects [---] mutations. These mutations dont just cause RP/LCA those are just the two biggest" [X Link](https://x.com/NattaCop/status/1940410145294700815) 2025-07-02T14:00Z [----] followers, [----] engagements "$ocgn What a blessing for companies pursuing treatments for rare diseases and an even greater one for the millions of Americans currently suffering. This legislation is insanely valuable. Yes companies like Ocugen will profit immensely but so will the American people who are currently stuck paying over $900 billion each year due to the economic burden rare diseases place on society. 👏 🥳 @Ocugen . good for companies with Orthan drug including #OCUGEN $OCGN This will be epic for our full pipeline The Bill was passed Congratulations to all https://t.co/JT5ZXbe4k7 @Ocugen . good for companies" [X Link](https://x.com/NattaCop/status/1940901334347309409) 2025-07-03T22:31Z [----] followers, [----] engagements "$ocgn Luxturna corrects a single mutation and holds .5%-1.5% of the RP market. Encelto is holds 0% of the RP market. A implant approved for MacTel type [--] slows degeneration by 33% provides 0% visual gain. Lasts [--] years on average. An early study for RP was conducted showed no visual acuity improvement and recorded no measurable slowdown in degeneration. OCU400 will hold 70%+ of the RP market. It's a one shot cure with a gene agnostic mechanism of action that corrects 150+ gene mutations. Studies show 80% of patients with RP and LCA report visual improvements with gains of up to 3+ lines on" [X Link](https://x.com/NattaCop/status/1942584078915792897) 2025-07-08T13:58Z [----] followers, [----] engagements "$ocgn [--] BLAs each year for the next [--] years. Buy now or chase later. Also 🔥 post Ocugen 👏" [X Link](https://x.com/NattaCop/status/1943379557576569193) 2025-07-10T18:39Z [----] followers, [----] engagements "$ocgn Owning a breakthrough in healthcare before the world knows feels incredibly rewarding. Were on the verge of a one shot cure a lifeline for those suffering from diseases that steal the gift of sight from millions. And like Ive mentioned before this is only the beginning. Ocugens innovative modifier platform is a new approach and it redefines the entire industry its a revolutionary shift in how we typically combat these challenging genetic diseases. Theyre rewriting how we treat inherited diseases and the $50B+ market theyre stepping into wont look the same after. This is what a paradigm" [X Link](https://x.com/NattaCop/status/1943394842819858604) 2025-07-10T19:40Z [----] followers, [----] engagements "$ocgn The commercialization phase has begun. New VP Abhi Gupta helped build Pfizers $5.5B gene therapy portfolio led a 200+ global team at Syneos and held leadership roles at J&J and Regeneron. You dont bring in someone like that unless youre gearing up to go worldwide. 🍻" [X Link](https://x.com/NattaCop/status/1945120886425837969) 2025-07-15T13:58Z [----] followers, [----] engagements "$ocgn Were less than [--] days away from finding out who our Korean partners are. 🍻 $ocgn You know the product is good when you see regional deals like the Korean deal. Royalty percentage far above industry average retained manufacturing control strong upfront and milestone payments and companies are paying this premium for a market thats only [--] percent the https://t.co/uLMZkbwS0J $ocgn You know the product is good when you see regional deals like the Korean deal. Royalty percentage far above industry average retained manufacturing control strong upfront and milestone payments and companies" [X Link](https://x.com/NattaCop/status/1945842433352401222) 2025-07-17T13:46Z [----] followers, [----] engagements "$ocgn Some call the latest news fluff tossing wild takes like not relevant. They post nonstop about this stock but couldnt tell you what words like pivotal/Orphan/RMAT/or FDA reforms even mean. Most stare at charts all day role playing as biotech experts while billion dollar catalysts stare right at them. OCU410ST dosed its first patient in their pivotal Phase 2/3 trial. Pivotal = BLA can be filed right after if successful. Endpoints are [--] months only [--] patients and dosing has started. No approved treatment exists for Stargardt a disease blinding children. With orphan pricing ($1.25M$1.5M)" [X Link](https://x.com/NattaCop/status/1947140315938537739) 2025-07-21T03:43Z [----] followers, [----] engagements "$ocgn Luxturna treated 0.5% of the RP market thats a global population of under 10K patients. They still did $120M in year one got acquired for $1.4B then later bought by Roche for $4.8B for a one mutation product Now compare that to Ocu400/410/410ST which are gene agnostic and target broad IRD populations in RP GA and Stargardt. Just Ocu410ST alone is going after a market 30x50x the size Luxturna targeted Factor in FDA reforms cutting BLA reviews to [--] months orphan pricing now securing prices at $1.25M+ no matter how many diseases a drug treats and rewards like priority review vouchers that" [X Link](https://x.com/NattaCop/status/1947390858262942006) 2025-07-21T20:18Z [----] followers, [----] engagements "$ocgn Most people have never heard of Ocugen. Thats exactly why its a goldmine. This isnt some hyped up penny stock. Its a pre commercial biotech entering the revenue phase backed by real science and billion dollar catalysts the market hasnt priced in yet. They recently landed a global licensing deal for only 1% of their products target market that proved they can generate massive upfronts milestone payments royalties in perpetuity and manufacturing revenue without dilution. This deal gave Ocugen the cash runway to file BLA next year. One more deal like that and suddenly their cash runway" [X Link](https://x.com/NattaCop/status/1949646735539921340) 2025-07-28T01:42Z [----] followers, [----] engagements "$ocgn ahh the classic traders spamming outrage over ER lol. this pre revenue stock gets attacked every earnings ya its wild I know 🤪 anyways for any real investor 🙋♂ this is exactly what we wanted to see. all systems are go to bring blockbuster products to market back to back to back over the next [--] years. well soon learn who our well-established leader in pharmaceuticals in Korea partner is. look at that premium licensing deal 🤤 Stocks gonna make a lot of retail with foresight rich along with this all star management team whose incentives directly align with us. Ownership is tied to" [X Link](https://x.com/NattaCop/status/1951422913921605712) 2025-08-01T23:20Z [----] followers, [----] engagements "mRNA is the sole reason Americans are waiting for a pandemic vax at all. [--] years of blocking every traditional platform egg cell vector just to force mRNA to the front. Billions in taxpayer funds funneled into synthetic tech while proven paths were sidelined. NIAID and select insiders got kickbacks. Now they pretend theres no plan B out there. There was Until they buried it" [X Link](https://x.com/NattaCop/status/1952877695819518150) 2025-08-05T23:41Z [----] followers, [----] engagements "@RickABright Youve been involved with CEPI heres some data you helped surface that shows there are cheaper safer and still fast alternatives to mRNA. Platforms like viral vector tech are proven scalable and next Gen ready. Curious where you stand on these options now" [X Link](https://x.com/NattaCop/status/1952879456428974223) 2025-08-05T23:48Z [----] followers, [----] engagements "Lmao Im sure taxpayers love knowing they were guinea pigs so Big Pharma could test run their next cash cow all funded by public dollars sold back at a premium all while safer options were buried. NIH insiders got royalties Fauci cashed checks and now sleep soundly convincing themselves itll save lives in the long run. Reality is it cost countless ones" [X Link](https://x.com/NattaCop/status/1952891885565165948) 2025-08-06T00:38Z [----] followers, [---] engagements "No one denies mRNAs potential for gene therapy or future treatments. Thats not the conversation. Were talking about vaccines where Americans were forced into one rushed platform that failed to stop COVID cost more to produce store and deliver and left better options blocked. Taxpayers got scammed insiders got rich and pharma funneled billions while Americans died waiting for alternatives that were never given a chance. If youre saying all thats justifiable because mRNA might someday treat cancer cool. Lets talk. Odd they didnt fund it for that purpose from the start imo" [X Link](https://x.com/NattaCop/status/1952895083449335834) 2025-08-06T00:50Z [----] followers, [---] engagements "mRNA isnt proven safe it failed to stop transmission required endless boosters and had higher adverse events like myocarditis. Viral vector clotting issues were tied to specific formulations and injection routes not the platform. Next-gen mucosal viral vector vaccines avoid that entirely its not even injected. CEPIs own data proves theyre fast scalable and effective" [X Link](https://x.com/NattaCop/status/1952897291435819030) 2025-08-06T00:59Z [----] followers, [--] engagements "Call me fucking stupid Youve been pushing pharma dogma for years claiming mRNA has zero safety concerns. Pfizer doesnt even back you their own trial data showed tens of thousands of serious adverse reactions and over a thousand deaths. Thats why they fought to hide it for [--] years. You didnt see a loved one drop dead after the shot. That doesnt make you informed doesnt make you right just lucky and dangerously fucking stupid. https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf" [X Link](https://x.com/NattaCop/status/1952906718436085881) 2025-08-06T01:36Z [----] followers, [---] engagements "Novavax was sidelined for years just like other traditional options like Covaxin while the gov funneled billions into mRNA and forced it down Americans throats until 80%+ had already taken it. Only after that did Novavax get approved but dont leave out a key fact. Its only approved for people who hadnt already taken mRNA. Thats less than 20% of the country. You think dropping an alternative years late restricted to a sliver of the population shows a fair market" [X Link](https://x.com/NattaCop/status/1952909658626376185) 2025-08-06T01:48Z [----] followers, [---] engagements "CEPIs own data shows other platforms like viral vector and protein subunit could reach human trials within roughly the same [--] week window after mRNA candidates were designed. Yet only mRNA got billions in funding and priority approval despite being FAR more expensive to manufacture requiring new ultra cold storage infrastructure nationwide expiring multitudes faster and offering short lived non sterilizing immunity. Meanwhile the cheaper proven platforms with room temp stability and proven long term durability were sidelined. All this for a few weeks of speed That not science bud. Thats" [X Link](https://x.com/NattaCop/status/1952917048646091243) 2025-08-06T02:18Z [----] followers, [---] engagements "Market hasnt priced in any of these catalysts yet. Right now were a pre rev bio with the cash to get us to BLA next year but not all the way to commercialization/revenue. The market reads that as dilution ahead and values us like it. Theyre looking at it broadly they dont know managements incentives are tied to fixed rate warrants meaning their upside only comes if the stock goes up. Reality is if youve done the research management will avoid major dilution because it directly benefits them. The company has already shown they can bring in cash by other means partnerships with big upfronts non" [X Link](https://x.com/NattaCop/status/1953605705640161798) 2025-08-07T23:54Z [----] followers, [---] engagements "No Return Ticket https://on.soundcloud.com/HrQV6kbdE0WfBieWU3 https://on.soundcloud.com/HrQV6kbdE0WfBieWU3" [X Link](https://x.com/NattaCop/status/1953635751889186988) 2025-08-08T01:53Z [----] followers, [---] engagements "$ocgn I hear about products all the time and often theyre brought up because people view them as a threat to this companies pipeline. Sanofi's early stage Gene Therapy for Wet AMD being the latest. I like explaining why they are not because it shows exactly why what we own is special. So heres why it is silly to see Sanofis as a threat when it is actually the opposite. This is just one story but the ending mirrors all the others. Sanofis drug is just another anti VEGF product for wet AMD only trying to cut the amount of shot visits patients need. Its basically J&Js Covid vaccine DNA delivered" [X Link](https://x.com/NattaCop/status/1968492365255205366) 2025-09-18T01:48Z [----] followers, [----] engagements "@m3alaam The cure to blindness first of many partnerships announced Ocu400 will be in Korea. Deal has extremely bullish terms for us with a top [--] Korean pharma. My page is full of details about this stock. 🍻" [X Link](https://x.com/NattaCop/status/1968754746128302135) 2025-09-18T19:11Z [----] followers, [---] engagements "$ocgn 1st off fam winning feels good. Bears your Ls are stacking nice. Hows that subscription 😜 2nd see how non of these analysts know the damn price of our drug tossing numbers like $200K lol. The price is on Ocugen's slide these peeps are lazy and overworked. Writing analyst articles about a stocks product giving PTs and everything and they dont even know the price. 🤯🤦♂ And no he's not being conservative. $750K in EU and $850K US is the absolute floor $1.5m the ceiling. No pharma is spending tens of millions on R&D for a drug not knowing what insurers are willing to pay for it. This is" [X Link](https://x.com/NattaCop/status/1970663439153725592) 2025-09-24T01:35Z [----] followers, [----] engagements "$ocgn a stock question answer that shows why the fundamentals here = growth. 💸 🏦 Management owns a total of 4.51m right to buy fixed rate options that are mostly vested (around 500k fully vest in 2026). Shankar for example owns 1.475m fixed at $1.25 and he doesn't need to exercise them for another [--] years and [--] months. You'd want to wait as long as you possibly can for the highest SP to exercise them because that = more ownership for free. A stock at $100 means that every share bought at $1.25 gets you [--] shares for free that's 1.18m shares that are worth $118M for free. This fundamental" [X Link](https://x.com/NattaCop/status/1971101744869605837) 2025-09-25T06:37Z [----] followers, [----] engagements "$ocgn company has nothing but big news to announce for months and years to come. Easiest buy there ever was. 💸 🏦 🚀 🌙" [X Link](https://x.com/NattaCop/status/1973779213196083662) 2025-10-02T15:56Z [----] followers, [----] engagements "$ocgn Bullish trends meet news packed conferences and business updates. Got to love where this is heading 🤑 EZ 💸 🏦 🍻 Nothing like hanging out and talking about stocks. What nobody is talking about is the weekly 200MA. Thanks for pointing it out @Eduardo21881249 . https://t.co/OGtcem6Kll Nothing like hanging out and talking about stocks. What nobody is talking about is the weekly 200MA. Thanks for pointing it out @Eduardo21881249 . https://t.co/OGtcem6Kll" [X Link](https://x.com/NattaCop/status/1973997836946874746) 2025-10-03T06:25Z [----] followers, [----] engagements "$Ocgn This👇is what BARDA is looking for. Sound familiar" [X Link](https://x.com/NattaCop/status/1592118702409146370) 2022-11-14T11:34Z [----] followers, [--] engagements "$ocgn A revolutionary breakthrough in gene therapy. 👏" [X Link](https://x.com/NattaCop/status/1885044604837519402) 2025-01-30T19:17Z [---] followers, [----] engagements "$ocgn This is a critical part imo. The lenders hold a senior security interest in Ocugens assets including its intellectual property as collateral. This means that if Ocugen wants to license or transfer its IP it would need lender approval since the lenders have a lien on it. If a big pharma deal were negotiated and Ocugen sought lender approval it would make perfect sense for the lender to respond Well release the IP for licensing once you pay off the secured portion of the loan and wed gladly accept shares. This is what we witnessed imo" [X Link](https://x.com/NattaCop/status/1885752554765930901) 2025-02-01T18:10Z [---] followers, [----] engagements "$ocgn Oh is it nice to see validation catch up to very bullish speculation. Soon the biggest news in companys history drops. 🍻🚀🌙👽 $ocgn This is a critical part imo. The lenders hold a senior security interest in Ocugens assets including its intellectual property as collateral. This means that if Ocugen wants to license or transfer its IP it would need lender approval since the lenders have a lien on it. https://t.co/sMmeqTBXtH $ocgn This is a critical part imo. The lenders hold a senior security interest in Ocugens assets including its intellectual property as collateral. This means that" [X Link](https://x.com/NattaCop/status/1888026563670954366) 2025-02-08T00:46Z [---] followers, [----] engagements "$ocgn 🐂 https://www.investing.com/news/analyst-ratings/ocugen-shares-rise-as-hc-wainwright-lifts-price-target-to-8-93CH-3867565 https://www.investing.com/news/analyst-ratings/ocugen-shares-rise-as-hc-wainwright-lifts-price-target-to-8-93CH-3867565" [X Link](https://x.com/NattaCop/status/1890075979592397082) 2025-02-13T16:30Z [---] followers, [----] engagements "$ocgn Next Big Pharma 💯 🚀" [X Link](https://x.com/NattaCop/status/1891859408524615759) 2025-02-18T14:36Z [---] followers, [----] engagements "$ocgn soon well learn who our partners are in Korea. The Korean deal conservatively projects $2.19b in total manufacturing revenue with $506m in profit after treating half of Koreas RP market (7500 patients). Even at just 3% yearly market capture (of [----] patients) Ocugen would still generate $65.8m/year in manufacturing revenue for Korea alone. Now add $2b+ in royalties (of [----] patients treated) plus millions in milestone payments. Whats the value of a deal like this with a company that will have no problem executing it Imo Id value it with more confidence. 🍻" [X Link](https://x.com/NattaCop/status/1950729660528197799) 2025-07-31T01:26Z [----] followers, [----] engagements "$ocgn FDA is opening the door for rare disease CGT (Cell and Gene Therapies) with self controlled trials external controls and registry follow up saving years and millions in development. This directly accelerates OCU400 and OCU410ST bringing them to market at record speed 🍻 #OCUGEN $OCGN.rare disease designation 👇👇👇👇 https://t.co/VggIqSNwpu #OCUGEN $OCGN.rare disease designation 👇👇👇👇 https://t.co/VggIqSNwpu" [X Link](https://x.com/NattaCop/status/1974228605401203096) 2025-10-03T21:42Z [----] followers, [----] engagements "$ocgn Very interesting Job description specifically: in-plant leadership for manufacturing at Ocugen technical expertise and leadership to Ocugens external manufacturing partners lead technology transfers collaborate across the network This screams a hub and spoke model. Ocugens Malvern facility being the hub that runs the playbook and launch supply. Future partners are the spokes via tech transfer. Yet the only public partner so far is Korea where Ocugen keeps manufacturing control. For India my pick is Bharat Biotech. They have growing CGT capacity so that deal likely trades local" [X Link](https://x.com/NattaCop/status/1974469306542072308) 2025-10-04T13:39Z [----] followers, [----] engagements "$ocgn Company has the drugs the expertise and a way to cross the blood brain barrier. As an early backer betting on a revolutionary concept Ive watched this modifier gene approach reshape the gene therapy landscape and how we tackle rare diseases. With concept now a reality does the future stop at rare diseases Not even remotely close. This is the start of a paradigm shift in healthcare. The days of bandaid subscriptions are ending and the age of real cures is coming. Practically everyone has been or will be affected by diseases like Alzheimers Parkinsons autism etc. The question isnt if this" [X Link](https://x.com/NattaCop/status/1975725813153866053) 2025-10-08T00:51Z [----] followers, [----] engagements "$ocgn Most will see Phase [--] for GA in [----] and shrug. The ones who know GA the therapy and this market understand the gravity of what was just announced. Dr. Jay Chhablan the Vice Chair of Clinical Trials at the University of Pittsburgh Medical Center Vision Institute just said the [--] month OCU410 data already looks superior to the FDA approved drugs when he compared them side by side. Retail needs to understand why this sets OCU410 up as one of the most valuable medicines ever lined up to hit the market. Why Im saying that OCU400 family keeps winning. OCU400 for IRDs OCU410ST for Stargardt" [X Link](https://x.com/NattaCop/status/1977731277647384699) 2025-10-13T13:40Z [----] followers, [----] engagements "$ocgn breakthrough therapy after therapy continues to get nothing but stellar trial results. This will be the biggest pharma in the world. 💯 📠" [X Link](https://x.com/NattaCop/status/1978576745339961583) 2025-10-15T21:40Z [----] followers, [----] engagements "$ocgn like a glove 🍻 FDA will be proactive in advancing decisions on medicines serving a key national priority: affordability domestic production or meeting an unmet public health need. https://t.co/oUuEsAnBQ2 FDA will be proactive in advancing decisions on medicines serving a key national priority: affordability domestic production or meeting an unmet public health need. https://t.co/oUuEsAnBQ2" [X Link](https://x.com/NattaCop/status/1978937545011388622) 2025-10-16T21:34Z [----] followers, [----] engagements "$ocgn welcome @drsmusunuri biotech GOAT. May more see just how much brighter youre making the world. 🍻" [X Link](https://x.com/NattaCop/status/1979231819305451544) 2025-10-17T17:03Z [----] followers, [----] engagements "$ocgn Company Galactic 🤣 ☠" [X Link](https://x.com/NattaCop/status/1979244894087782577) 2025-10-17T17:55Z [----] followers, [----] engagements "$ocgn couldnt ask for better results. 🍻🔥" [X Link](https://x.com/NattaCop/status/1979444405691126129) 2025-10-18T07:08Z [----] followers, [----] engagements "🧵 $ocgn Hot take: stocks push to $2.5 will be followed by a Japan partnership announcement and Astellas clearly looks like the partner. Why Astellas" [X Link](https://x.com/NattaCop/status/1979695816655937621) 2025-10-18T23:47Z [----] followers, [----] engagements "Astellas is built for retina after the Iveric deal. Huge Japan field force. Real PMDA muscle. No RP conflict of interest. They know pricing and access and they move paperwork fast. How does Japans market look" [X Link](https://x.com/NattaCop/status/1979695818518196503) 2025-10-18T23:47Z [----] followers, [---] engagements "Use Korea as the benchmark. Korea deal was about 7.5M upfront with [--] percent royalties and Ocugen supplying drug. Scale by market size plus Japan pricing power and the math gets spicy. Spicy" [X Link](https://x.com/NattaCop/status/1979695823043887396) 2025-10-18T23:47Z [----] followers, [---] engagements "My range for a Japan only license Worst case 25M to 45M upfront Base 50M to 80M upfront Stretch 90M to 120M upfront Royalties [--] to [--] percent Ocugen likely keeps manufacturing on a cost plus margin. Math check" [X Link](https://x.com/NattaCop/status/1979695827099766893) 2025-10-18T23:47Z [----] followers, [---] engagements "Quick math check Assume bilateral price in Luxturna class. Treat [---] to [---] patients per year as capacity ramps. That is roughly 15B to 70B in yearly net sales. About 100M to 470M dollars at simple FX. At [--] percent royalty that is 20M to 100M a year to Ocugen before any supply margin. Speed" [X Link](https://x.com/NattaCop/status/1979695829998039383) 2025-10-18T23:47Z [----] followers, [---] engagements "Why Japan can move fast PMDA can accept foreign clinical data under ICH E5. Examples: Luxturna and Zolgensma. No need to redo the world. Our package fits that playbook" [X Link](https://x.com/NattaCop/status/1979695831684112697) 2025-10-18T23:47Z [----] followers, [---] engagements "Bottom line If Astellas takes Japan the package lands at a 3x to 6x multiple of Korea with double digit royalties and Ocugen keeping the manufacturing lever. This deal is going to be so f**king 🔥😉🤑 Do you Im am long. 🍻" [X Link](https://x.com/NattaCop/status/1979695833311514860) 2025-10-18T23:47Z [----] followers, [---] engagements "$ocgn Why build an AI team in India Because Ocugens gene agnostic platform has shown it can correct over [---] mutations. Recent FDA and global moves let platform therapies expand into related mutations or indications without a brand new BLA or new pricing negotiation. Many drugs could treat more but the risk stopped companies from trying. That barrier is gone now. For a platform that addresses over [---] mutations across multiple diseases this opens a path to reach millions who have nothing today. AI will help companies map the addressable markets design smarter trials and process the data at" [X Link](https://x.com/NattaCop/status/1980489896709247276) 2025-10-21T04:22Z [----] followers, [----] engagements "$ocgn very few understand yet but it will be very apparent to everyone soon. 🍻" [X Link](https://x.com/NattaCop/status/1981550953267679502) 2025-10-24T02:38Z [----] followers, [----] engagements "$ocgn If you are invested or thinking about it watch the latest panel discussion with the CEO Shankar. You have to fill your name and email and then the video will pop up. Its 40mins+ long but very worth the watch. Any investor or potential investor who watched this would put their money on Ocugen. While everyone else is focused on small progress Ocugen is focused on a paradigm shift and their drugs have proved that theyre just that. Basic summary: Others talked about how there's plenty of room currently in the market for other treatment options that they see commercial success for drugs that" [X Link](https://x.com/NattaCop/status/1982244501784768954) 2025-10-26T00:34Z [----] followers, [----] engagements "$ocgn New peer reviewed paper on OCU400: Perfect safety Vector stays in the eye no anti NR2E3 issues NR2E3 expression holds This paper de risks our BLA and sweetens the math for partnership. Bullish sentiment tailwind inbound I think so. 🍻" [X Link](https://x.com/NattaCop/status/1983651447746285917) 2025-10-29T21:45Z [----] followers, [----] engagements "$ocgn this stock is considered too risky in the eyes of big money and institutions. With phase [--] trials ongoing these major funds will wait until more data/BLA before investing. For retail who actually follow the pipeline have watched trial after trial get stellar results of 100% safety and 100% efficacy. When data rolls in analysts have to do real math. Weve already seen $8+ SP targets with most modeling 100k pricing. Our product and Gene therapy comps in general will live around $850k to $1.25m. First drug to market is for Retinitis Pigmentosa. Hundreds of thousands of patients worldwide" [X Link](https://x.com/NattaCop/status/1985431549635150027) 2025-11-03T19:39Z [----] followers, [----] engagements "$ocgn Exactly the update I wanted to see. OCU400 set to start a rolling BLA in 1H [----]. OCU410ST 50% enrolled and on track for a 1H [----] BLA filing. Cash on hand extends into [----] if Aug warrants are fully executed. EMA/CHMP accepted a single U.S. trial for the Stargardt MAA. Korea license for OCU400 reiterated $7.5m upfront milestones structured as $1.5M per $15M of sales(projecting $180M+ in first [--] years off milestone payments) 25% royalties and Ocugen supplies drug (keeping manufacturing control). OCU200 enrollment targeted to complete 4Q [----]. OCU410(GA) full phase [--] data in 1Q 2026." [X Link](https://x.com/NattaCop/status/1986081806177952037) 2025-11-05T14:42Z [----] followers, [----] engagements "$ocgn We saw patient going blind after patient go in and get treated. Then we saw tearful and joyous testimonials every year since. 100% efficacy. 100% safety. And thats not just one product. Were seeing it platform wide RP Stargardt GA and now autism looks to be next. Got our eyes on Alzheimers Parkinsons and more too. You can see a pre Rev bio just another speculative play or try to gamble on the SP as it fluctuates cents daily. Im seeing reality and science tell a once in a lifetime story and cant help but capitalize on the most discounted bio on the market.🍻" [X Link](https://x.com/NattaCop/status/1986434836714922324) 2025-11-06T14:05Z [----] followers, [----] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@NattaCop TheUrbanFarmer
TheUrbanFarmer posts on X about $ocgn, ocgn, money, company the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.
Engagements: [-----] #
- [--] Week [------] +25%
- [--] Month [------] +312%
- [--] Months [-------] +33%
- [--] Year [-------] -7.10%
Mentions: [--] #
- [--] Week [--] +100%
- [--] Month [--] +113%
- [--] Months [--] +53%
- [--] Year [---] +73%
Followers: [-----] #
- [--] Week [-----] +0.81%
- [--] Month [-----] +0.65%
- [--] Months [-----] +8%
- [--] Year [-----] +27%
CreatorRank: [---------] #
Social Influence
Social category influence finance countries stocks technology brands celebrities exchanges currencies us election social networks cryptocurrencies
Social topic influence $ocgn #7, ocgn, money, company, japan, stocks, pharma, next gen, events, imo
Top accounts mentioned or mentioned by @ocugen @moreflax @drsmusunuri @robertkennedyjr @rickabright @elonmusk @nattacop @awareofsilence @bsdyork @usfda @crisisparade @danibeckman @martymakary @realdonaldtrump @amldean19 @bambossie81 @cgtlive @pirateye2 @un @scienceunga
Top assets mentioned Novartis AG (NVS) Stellar (XLM) Pfizer, Inc. (PFE) Verge (XVG) Fusion (FSN) Alphabet Inc Class A (GOOGL) Spotify Technology (SPOT)
Top Social Posts
Top posts by engagements in the last [--] hours
"$ocgn Come step outta your shoes for a second. Might just realize why certain ppl act a certain way. Can you guess who owns these shoes 🤭 Imagine you sell covered calls shares locked up at a strike price and expiration date. You're confident in your strategy to generate"
X Link 2023-06-29T21:48Z [---] followers, [----] engagements
"I believe it 💪 just watch out for the snakes in the grass who have incentives to spread that sort of fud. Sorry if I was blunt its just Ive been here since this company went public(check out my vid Dj vu where I showcase these same fears that were being spread back in 2019/2020 before the 🚀 to ATH). Ive been through RS fears before and have heard all the fud imaginable too many times to count. Most of the time facts can easily disprove the fud. Fact is Ocugen has plenty of time to regain compliance I was here during the only RS vote in the companies history and that vote only came at the"
X Link 2023-08-10T16:27Z [---] followers, [---] engagements
"@RickABright Exactly Rick. Its a shame to see such results after all that. We urgently need to fund fresh cost-effective platforms with ethical companies that value people over profits. Time to pivot towards innovation that helps all and guarantees fair access to life-saving solutions"
X Link 2023-08-13T21:53Z [---] followers, [----] engagements
"@Pirateye2 You bring up a good point. Why is Covaxin sidelined A traditional vax thats economical proven safe and effective in recent USA trials with manufacturing ready to go. Government sidelines that giving the people no other option but mrna at $100+ a pop Its sus no doubt"
X Link 2023-08-13T23:09Z [---] followers, [---] engagements
"@AWAREOFSILENCE With news comes volume"
X Link 2023-09-01T16:59Z [---] followers, [--] engagements
"$ocgn The new Covid variants carry up to [--] mutations in their spike protein which will circumvent these new mRNA booster shots just like all the previous rounds. The mounting pressure on Gov to accelerate the development of next-generation vaccines is reaching an all-time high. Covid exhibits one of the highest mutation rates among all viruses. The most economically viable approach to combatting Covid is through a viral vector platform as demonstrated by years of collected data. Ocugen already possesses this platform and inhalation technology proven to be effective with real-world data. A"
X Link 2023-09-01T18:58Z [---] followers, [----] engagements
"$1.8 billion to purchase [--] million mRNA vaccines for children. $1.8 billion for these mRNA vaccines that wont stop transmission have rare but serious side effects and will cost a significant amount to store and transport all for a virus that children are hardly affected"
X Link 2023-09-08T01:14Z [---] followers, [--] engagements
"@RickABright @UN @ScienceUnga Nice cant wait Helping save lives while saving everyone billions at the same time thank you #100DaysMission"
X Link 2023-09-08T06:45Z [----] followers, [---] engagements
"@Chef_Enrico Not this time. Gov needs a genuine vaccine"
X Link 2023-09-10T16:06Z [---] followers, [--] engagements
"@ChefFrankfalcon @MoreFlax Because the world will recognize our vaccine as safe. Next gen funding is to fast track phase2b and up. They just need to know the vaccine is safe since the phase 2b+ will figure out the correct dosing for best efficacy. Our vaccine is Sealy Certified safe in a very large P3.🍻"
X Link 2023-09-17T17:27Z [--] followers, [---] engagements
"$ocgn if youve been paying attention you would be very proud of Ocugens achievements and very excited about the news to come. 🍻"
X Link 2023-09-26T20:30Z [---] followers, [----] engagements
"$ocgn Us after Ocu500 funding gets announced"
X Link 2023-10-04T02:17Z [----] followers, [----] engagements
"$ocgn a glimpse of the future its a shining light big news on deck our stock takes flight. With funding secured our rocket ignites what fool misses out on such delights"
X Link 2023-10-07T23:30Z [---] followers, [----] engagements
"$dpls Neural Signals Inc.s technology stands out due to its remarkable longevity and fast/accurate processing of brain-to-speech data. By placing their implant deep in the cerebral cortex they benefit from strong signal strength. This strength in combination with a brain-to-speech algorithm derived from Kennedys own data enables Neural Signals to achieve near real time brain-to-speech processing which is significantly faster compared to existing market technologies. The key to their longevity lies in their neurotrophic electrode-tipped glass cones. With this approach the brain grows into the"
X Link 2023-10-08T16:02Z [---] followers, [----] engagements
"@TanyaWa21545395 $18 came and went quick would of been a silly time to sell anyways since we would of definitely flew way way higher with EUA. Next launch will be a lot less volatile since our floor will be made of💰imo. 🍻"
X Link 2023-10-10T00:48Z [---] followers, [---] engagements
"We truly possess the best of both worlds. Own the only two approved delivery systems currently being used today while owning the most cost effective and safe next gen vaccine platform. Our viral vector platform can carry/deliver a very wide range of messages from vaccines to gene therapies our vectors can carry the message and deliver it safely. Our platform doesnt require unstable messaging like Mrna and doesnt need any toxic adjuvants to trigger an immune response. Our vectors trigger a immune response the same way nature intended. Introduce a message to a vector place it in a chamber and"
X Link 2023-10-10T21:41Z [--] followers, [----] engagements
"$ocgn We will be green on the weekly chart for the next year. The bears have absolutely nothing at all now. Sure people could of feared a RS or the need to dilute when they didn't know if funding was coming or not. Now we have a straight path to a multi-billion dollar market without having to spend a dime. 😂 Tell me ocgn is a bad investment and l'll know you're either a fool or you're lying lol. We will keep moving on up week after week there's just really no other place for us to go. 🍻"
X Link 2023-10-11T09:06Z [---] followers, [----] engagements
"$ocgn Only market ready drugs do head to heads. Head-to-head studies in the medical field are done on market-ready drugs and devices because these products have undergone extensive testing received regulatory approval and established known safety and efficacy profiles. This approach ensures ethical patient treatment provides practical comparisons with existing standards and offers reliable data for informed healthcare decisions. While innovation is crucial head-to-head studies with approved products are essential for advancing medical knowledge and treatment options within the current"
X Link 2023-10-20T17:25Z [---] followers, [----] engagements
"$ocgn Same bears who were saying it's to bad Ocugen owns Covaxin and not BB's nasal vaccine because that's the future of vaccines. Now act like Ocu500 is not even developed after Ocugen gained exclusive rights. "The study involving Ocugen's vaccine will be administered via both intranasal and inhaled routes and is designed to help answer an important question - does an inhaled COVID-19 vaccine provide greater immune response than the same vaccine administered through a nasal spray." They want you to believe Ocu500 is not even phase [--] ready. They want you to believe that the NIH is"
X Link 2023-10-23T16:17Z [---] followers, [----] engagements
"Profound existential questions such as Who are we and Why are we here may elude us as long as our consciousness remains intertwined within the fabric of our own unique space and time. Perhaps conscious enlightenment only comes once we achieve equilibrium with the cosmos liberating our conscious minds from the constraints of time and space until our conscious superposition collapses once again"
X Link 2023-12-03T19:35Z [---] followers, [---] engagements
"@ilikethestocks They had to submit their plan to gain compliance to Nasdaq Nasdaq accepted this plan and granted them another extension. I trust management and I trust Nasdaqs judgment. Ive seen this play out b4 when ocgns pipeline was just a fraction of what it is today im not worried💯"
X Link 2023-12-11T21:34Z [---] followers, [---] engagements
"Gov will use consortiums like RRPV/BIOMAPS as funding vessels for Project Next Gen. Gov wants long term pandemic Preparedness with the ability to respond within [---] days. Their plan is to give companies with the right products incentives like OTAs(other transactional agreements) to boost capabilities and maintain necessary production rates. Unlike traditional Gov funding OTAs are flexible give companies creative freedom and provide companies intellectual property rights ect. Think long term partnership where Gov provides guaranteed long term demand so companies will continue to develop the"
X Link 2023-12-17T02:55Z [---] followers, [---] engagements
"$ocgn Gov will use consortiums like RRPV/ BIOMAPS as funding vehicles for Project Next Gen. Gov wants long term pandemic Preparedness with the ability to respond within [---] days. Their plan to achieve this is to give companies who own the right products incentives like OTA's (other transactional agreements I've mentioned them b4 🤑) to boost capabilities and maintain necessary production rates. Unlike traditional Gov funding OTA's are flexible give companies creative freedom and provide companies intellectual property rights ect. Think long term partnership where Gov provides guaranteed long"
X Link 2023-12-18T20:36Z [---] followers, [----] engagements
"$ocgn Ocugen received alignment on key aspects of the Phase [--] study designincluding the study endpoint patient enrollment strategy and study duration of one year. The Phase [--] clinical trial will enroll a broader group of RP patients including patients with the most common RHO gene mutation based on OCU400s potentially gene-agnostic mechanism of action. 🔥"
X Link 2023-12-21T11:51Z [--] followers, [----] engagements
"$ocgn Shout out to all the real Gs invested in the next major player in pharmaceuticals our road to $10b+ MC is underway. To all the day traders who spent these days spreading fud on a small cap bio set to make a significant impact on lives well heres to hoping youll figure it out one day. Cheers to the journey to come 🍻"
X Link 2023-12-26T23:11Z [---] followers, [----] engagements
"You wont be alone fam. I secured acreage back when our pipeline was just a fraction of what it is today. Many bios claim to be developing market-disrupting products but only a small percentage actually prove them a reality. This is what makes investing in small cap bios so risky. So many horses to bet on but only one becomes industrys standard. Choose wisely and you could own a piece of a company who holds exclusive long term rights to a market worth billions. Ocugens entire pipeline crafted through years of hard work is now proving itself to be the future industry standard. Early backers"
X Link 2023-12-27T02:29Z [--] followers, [---] engagements
"@AWAREOFSILENCE Happy new year fam Hope the 🐻s like death metal"
X Link 2023-12-30T20:26Z [---] followers, [---] engagements
"$ocgn you may be wondering what Ocugen is all about why we are up how much higher can we go is a drop coming or is there more news on the way Well I made a vid about all that. From Gov funding multiple drugs with fast tracked phase 3s one of only [--] companies to receive RMAT designation for multiple products set to disrupt multibillion 💵 industries licensing deals partnerships Consortiums with OTA Gov funding going to members(Ocugen being a member) B&M Gates Foundation funding a pipeline that will continue to evolve and more is what Ocugen has on the table. Also the company is fundamentally"
X Link 2024-01-02T11:22Z [---] followers, 14.4K engagements
"@bsdyork Ive been adding lately but once compliance comes the party wont stop there. Imo any true investor here will win this stock has $10b+ MC written all over it. 🍻"
X Link 2024-01-02T15:46Z [---] followers, [---] engagements
"$ocgn If youre curious on how Ocu500s study will most likely pan out well McMasters did a study comparing our ChAd vectors with Cansinos Adenovirus vectors as an inhalation(pics/link below). NIH will now compare our inhalation vs Nasal delivery devices. I assume inhalation will outperform nasal and anything else but if Nasal shows good results too Barda/B&M may want it too for its ease of use qualities. 🍻"
X Link 2024-01-09T19:34Z [---] followers, [----] engagements
"$ocgn if youre worried then you havent done enough DD. Huge news is coming and no it isnt India funding our R&D facility lol. Think more in terms of Global Access Everywhere. Deja vu fam will drop a new vid tomorrow. 😉🚀🍻"
X Link 2024-01-15T04:23Z [---] followers, [----] engagements
"$ocgn just wanna be crystal clear about what the DD suggests and what I mean by Deja Vu. What I mean is we moon Q1 with major PR to comfortably gain compliance with a pipeline thatll only bring more news to come. 🍻"
X Link 2024-01-18T08:59Z [---] followers, [----] engagements
"$ocgn did you know that our Inhalation platform may require only [---] gallons of drug substance for the production of [---] million doses In the McMaster trials(pic below) our ChAd vectors outperformed Cansinos Adenoviruses offered maximum protection at an even smaller fraction of the dosage needed compared to intramuscular vaccinesa major selling point. This efficiency allows us to profit more while charging considerably less. Investing in our platform is a win-win for everyone. Our technology involves cells with a message mixed with water utilizing cutting-edge delivery tech to deliver it to"
X Link 2024-01-25T18:50Z [--] followers, [----] engagements
"@bsdyork Before compliance deadline 💯 🚀🌘"
X Link 2024-02-04T00:14Z [---] followers, [---] engagements
"$ocgn idk tough choice"
X Link 2024-02-10T19:08Z [---] followers, [----] engagements
"$ocgn An extended runway by bullish means like a premium DO/licensing deal/Gov funding/B&M funding ect will completely secure our future. This is when our whole pipelines value finally gets recognized by the market. We have multiple products starting phase [--] this year both RMAT designated fast tracked one of them being our cure to blindness and that trial has only a [--] year duration and will start anytime now (early this year). We also have Gov funding for vaccines expected to come funding that will go towards manufacturing for rapid preparedness and in forms like OTA's which are super"
X Link 2024-02-20T05:15Z [---] followers, [----] engagements
"Yes to partnerships no to a buyout. Ocugen is poised to become a major player in the pharmaceutical industry. Shankar didnt leave Big Pharma after successfully launching their most profitable product acquiring all these patent rights and establishing a robust pipeline and team just to sell it all away to Big Pharma right as were gearing up for commercialization. The company lacks incentives to sell out even at a substantial premium. Consider managements fixed-rate warrant structure which vests over years and doesnt expire for ten years. Most of these warrants being fixed at a higher price"
X Link 2024-02-21T20:58Z [---] followers, [---] engagements
"$ocgn If I shared what our actual SP should be based on Ocu400 revenue projections for US/EU alone I would come off as a crazy person. Once partnership provides the cash to secure our pipeline $18 would be considered a massive discount this is what the facts/math shows not hopes/dreams. Do a risk adjusted NPV on just our Ocu400 series If youre looking to blow your mind. Craziest thing this is just the beginning. Ocugens journey from a small cap pre rev Bio to Big Pharma has begun and this is the year the world takes notice. Own a piece before they do I certainly will 🍻🚀"
X Link 2024-03-18T05:22Z [---] followers, [----] engagements
"$ocgn Pharma USA event starting the 26th Big Pharma partnership for Ocu400 our gene agnostic therapy World Vaccine Congress starting April 2nd next generation inhalation & nasal vaccine for Operation Next Gen. with the events to come our news on deck overseas partners breakthrough products and the new members of our team like Connie Collingsworth one of the founders of the B&M Gates foundation. Ocugen is poised to have one hell of a year. [----] the year of global recognition. 🍻"
X Link 2024-03-26T13:20Z [---] followers, [----] engagements
"$ocgn congrats fam we did it"
X Link 2024-03-26T21:42Z [---] followers, [----] engagements
"Covid revealed our pandemic unpreparedness. Operation Warp Speed emphasized speed but lacked the science and transparency. While bad actors celebrated success while they got the f outta dodge were left with a mess and vulnerable. Grateful for voices like @RickABright who continue to fight the good fight no matter the cost. One of the few public health figures I trust who always put science/people first with a history to back that claim. As the world shifts focus on preparedness and response its nice knowing theres some voices of logic and reason at the table especially as a case of avian flu"
X Link 2024-04-06T03:31Z [---] followers, [----] engagements
"$ocgn will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference presented by Noble Capital Markets taking place from April [--] - [--]. 🍻🐂 https://ir.ocugen.com/news-releases/news-release-details/ocugen-participate-fireside-chat-emerging-growth-virtual/ https://ir.ocugen.com/news-releases/news-release-details/ocugen-participate-fireside-chat-emerging-growth-virtual/"
X Link 2024-04-12T11:49Z [---] followers, [----] engagements
"$ocgn RP affects nearly [--] in [-----] in [----] people worldwide. In regions like United Arab Emirates (UAE) Saudi Arabia Kuwait and others the disease is more prominent affecting nearly about two and half times of other countries like the US and Europe. Commercial rights to this region will not be cheap imo. 🍻"
X Link 2024-04-12T12:25Z [---] followers, [----] engagements
"@StocksNdCrypto @Mr_Yambone https://twitter.com/nattacop/status/1780749131570717104 @Dfwmb123 No these are not shares bought these are warrants awarded. They give her the right to buy those shares at $1.59. They become available in chunks over [--] years and expire after [--] years. 🍻 https://twitter.com/nattacop/status/1780749131570717104 @Dfwmb123 No these are not shares bought these are warrants awarded. They give her the right to buy those shares at $1.59. They become available in chunks over [--] years and expire after [--] years. 🍻"
X Link 2024-04-18T02:03Z [---] followers, [---] engagements
"No because she lead the phase 1/2 these shares are awarded to her for the stellar results she got. Results that just expanded our phase [--] to treat broad RP which increases the target market of Ocu400 by multitudes and big pharma cant really buy some rights to a drug without knowing the target market. These shares are not some perfectly timed scheme to get rich this is just literally the process and the natural order of things. Next in line should be finalizing the BP deal. 🍻"
X Link 2024-04-18T02:28Z [---] followers, [--] engagements
"$ocgn bulls here whove spent this last year accumulating are about to transform into whales. Market is prioritizing books over pipeline but our pipelines value is on the verge of recognition. Big Pharma is at an inflection point their bread and butter products face patent expiration. To persevere pharma giants are looking for new targets that give them a leg up before that patent cliff. Products like monoclonal antibodies is what saved pharmas top line back then. The inflection point now is emerging innovations in cell and gene therapies targeting oncology ophthalmology rare diseases and"
X Link 2024-04-29T13:34Z [---] followers, [----] engagements
"$ocgn Dont forget that near the end of June well be listed back on the Russel3000. Remember how tute ownership started to fall off a cliff when we got booted from Russel last June Well many tutes have rules for risk management where they only invest in Russel listed companys. So think about the major news we have lined up the timing of it all and the absolute FOMO it will bring as were listed back on the Russel while tutes are all fighting to secure their ownership. Imo theres a reason why Zhang the only insider who bought the lows and sold the all time highs the last time around decided to"
X Link 2024-05-10T13:29Z [---] followers, [----] engagements
"$ocgn Because of a partnership with big pharma. Think about the news that we have lined up. If we want ocu400(and more later) to hit the market globally as quickly as possible then partnering with a big pharma company with a global footprint already is the best way to do this. Big pharma will of course want to own some stock in Ocugen just like BB owned a small amount of Ocugen when we partnered with them for Covaxin just this will be bigger than that. If you look at Novartiss partnership with Roche their partnership came with Novartis owning around a 30% stake. Their partnership formed in"
X Link 2024-05-11T20:54Z [---] followers, [----] engagements
"$ocgn The Series C distribution on the 22nd will secure Ocugens current control (voting power) protecting it from potential large purchases by future partners which prior to Series C could have gained excessive voting power. Following this there will be a vote to increase authorized shares for the partnership. Then the company will announce the biggest news in its history: a partnership with a major pharmaceutical company granting Ocugen a global footprint for their revolutionary drug(s). Ocugen will transform from a speculative bet into a cash-strong biotech with a clear path to global"
X Link 2024-05-15T12:47Z [---] followers, [----] engagements
"No its just something that I follow and know will come on the last trading day of June. Many institutions wont touch a non Russel listed company as part of their risk management strategy. Its why you see institutional ownership explode after June [----] and why it plummeted after June [----]. Ive already seen this movie before its why Ive said deja vu for the last year. If youve enjoyed it thus far just wait till you see whats to come. Spoiler alert this sequel has a different and more bullish ending. 😉🍻"
X Link 2024-05-18T23:03Z [---] followers, [---] engagements
"$ocgn late this month/next month should be the time they 🌙 us. Shorts failed big time even had the perfect fud to pump. Bulls will be accumulating in the $1.5 range till 🚀 at least I will be. Life changing money coming soon 🍻 💰 🏦"
X Link 2024-06-10T19:20Z [---] followers, [----] engagements
"$ocgn only a few close to us no one doing it like us multi-billion dollar markets exclusively ours and billions in yearly revenue in our horizon. This is Ocugen soon to be the next big pharma. Like other big pharma companies like Pfizer Novartis GSK ect dividends and share buy backs are a likely outcome here. Buy hold help the world while helping your wallet. Only winners here. 🍻 #OCUGEN look what they think of us."Pivotal" only few companies even close to us https://t.co/WdVsNiBpZ0 #OCUGEN look what they think of us."Pivotal" only few companies even close to us https://t.co/WdVsNiBpZ0"
X Link 2024-06-18T21:44Z [---] followers, [----] engagements
"$ocgn Remember that one time when the director of NIAID who was also lead for the White House Covid Task Force insisted that mRNA vaccines were all we needed fast-tracked approvals based on trials done on eight mice while blocking any path to market for traditional vaccine options even ones that had Phase [--] data overseas Remember how mRNA is so unstable that Gov needed billions of taxpayer dollars to buy next-gen sub-zero freezers just to keep them from spoiling for a few months Remember how they shoved it down our throats telling us were lucky and privileged to have the government spend our"
X Link 2024-07-31T07:46Z [---] followers, [----] engagements
"$ocgn stock market had its worst July in a decade and bears still cant take us down even after an offering lmao. Theres no where for this stock to go but up from here. Major news is coming back to back including today where Ocugen will now bring in revenue from a product through early access. Cheers bulls today our road to be pharma starts and its gonna be one hell of a ride. 🍻 New song Bag Like That"
X Link 2024-08-05T19:30Z [---] followers, [----] engagements
"$ocgn big money has their eye on the next big pharma. Do you Blackrock $14.1m shares added haha LFG #WinnersWin"
X Link 2024-08-13T23:22Z [----] followers, [----] engagements
"@nirjovega Its not 13f typically reflect long positions and large institutions like BlackRock report only their long equity holdings in these reports. When they short they use different mechanisms or accounts that wont be reflected in a 13F filing. 🍻"
X Link 2024-08-13T23:41Z [----] followers, [---] engagements
"The American people deserve the truth. FDA do you remember Covaxin The traditional whole-virion vaccine that you forced to jump through every bureaucratic hoop while you were fast-tracking mRNA boosters based on trials conducted on just [--] mice You urged the company to seek approval through a U.S. BLA trial and they didspending over $100 million on a massive Phase [--] trial that yielded top-line data showing broad protection against all variants of concern. Yet despite this you never approved an alternative traditional vaccine option after they successfully navigated your obstacle course. Why"
X Link 2024-08-22T23:58Z [----] followers, 143.4K engagements
"$ocgn LFG Our day is coming and Im so damn excited to finally see it come to fruition. Science and the good guys will prevail for the worlds sake they must 🔥"
X Link 2024-08-23T16:57Z [----] followers, [----] engagements
"Novartis a company with a Gene therapy that also treats RP targeting mutations that affect .5-1% of the total RP market brought in $45b in [----]. Their market cap is roughly 6x this at $262b. So if we assume the same 6x multiplier off $30b in rev off just one of our products(imo thats low considering our other gene therapy would be just around the corner to cure AMD would forecast a lot more yearly revenue) that would put us at a $180b MC or $625sp. Way the company is structured too incentivizes growth so with that much cash on hand dividends and buy backs are likely. Theyll probably forward"
X Link 2024-08-27T21:11Z [----] followers, [---] engagements
"@salvador_wolf @MoreFlax Just what I see coming based on a whole lot check my other commented above I mention some 🍻"
X Link 2024-08-28T16:57Z [----] followers, [---] engagements
"Its almost like some stocktwits bear trolled her like how they try to get investors to vote against a company and she actually just ran with it. Just what everyone needs right now especially investors here the biggest market crash with money pouring out of growth stocks and the most volatility the market would ever see constantly just in time for our big news too. Ffs 🤦♂ I get people having beef with trump sure dudes no saint and Im glad were seeing RFK instead of fauci this time around. With what Kamala is proposing though I truly dont care if trump banged your wife theres literally no"
X Link 2024-08-28T23:22Z [----] followers, [---] engagements
"Definitely not. The fundamental structure of a company is just as important as its management and products imo. That structure reveals executive incentives and shows the paths management is likely to take. How many times have we seen investors buy into a companys vision only to get burned because the structure incentivized decisions that didnt align with shareholder interests I see it all the time. For example when a CEO is getting a percentage of the float every year and then they announce a reverse split it doesnt surprise me. But Ocugens structure is an investors dream. Its built to"
X Link 2024-09-08T01:06Z [----] followers, [---] engagements
"(Part 2) Ocu200 is a fusion of two molecules widely recognized for their cancer-fighting properties. Studies show that Tumstatin halts the formation of blood vessels that supply tumors effectively starving cancer cells while Transferon boosts the bodys ability to recognize and destroy cancer cells. If Ocu200 demonstrates that the fusion of these two molecules does what these studies suggest the standalone molecules dothat it will have synergistic effects when combined with anti-VEGF drugs like Lucentisit wont just be a therapy for AMD. It would become a new tool for fighting a wide range of"
X Link 2024-09-12T18:52Z [----] followers, [----] engagements
"The answer is simply business. Were a pre rev bio holding many cards but limited funds. We needed to focus on what we felt had the greatest likelihood of success first before continuing with the rest. Lucky for us Ocu400s bet has yielded amazing results and govs handling Ocu500 R&D. Youre right though Ocu200 developments does suggest something imo that something is confidence in our abilities to fully develop it though. 🍻"
X Link 2024-09-13T06:43Z [----] followers, [---] engagements
"Im like why do you sound so familiar. The nonsense and aggressive tone over something so trivial and easy to look up. Screenshots of something chat gpt wrote portrayed as some source for your bs when the companys stated SEC filed and all the easy to google articles/interviews are everywhere going over every detail of the CMC issue and hold(was Covid btw our manufacturer pivoted to manufacturing vaccines). Then it hit me I remember who you are. Whats up Phil you absolute legend your style of ignorant stupidity is so unique that it reminded me of our last convo over a year ago before your"
X Link 2024-09-13T13:27Z [----] followers, [---] engagements
"Literally nothing this week is a historically bad week for the market and bears used it to short and bash the stock and retail panicking like some fundamental shift happened with the company. Nothings changed Shankar even mentioned theres lots of interest in Ocu410 and they plan to partner with big pharma for Ocu410 in Q1 before they go phase [--]. Shorts/institutions are taking advantage of retail load and hold with big money and youll win big launch at the latest q1 imo. 🍻"
X Link 2024-09-24T20:13Z [----] followers, [---] engagements
"Ah I see now. Youve got to dig deeper into how a company is fundamentally structured if you want to predict what management will do next. I think Ive seen you around for awhile I dont think youre a troll so Ill share some key insights and hope Im not just wasting time. I wasnt randomly guessing when I spent a whole year posting about how Ocugen will choose two [---] day extensions and hit compliance in Q1 this wasnt based on hopium. Take MULN as an example. I called that they would reverse split before they did the first one. Why would I think that Because the CEOs compensation is tied to a"
X Link 2024-09-25T00:57Z [----] followers, [---] engagements
"$ocgn Us early investors are taking a calculated risk on products projecting $4b+ in yearly revenue. If things go as planned then even the most modest valuations will yield us the bulk of growth near term. For example Eli Lilly brings in $45b a year in revenue with a market cap of $834b valued at 18.5x yearly revenue. This is on the higher side of the average (10x-20x) but not unreasonable some bios see 30x their yearly revenue if the market is extra bullish on their future. Say for whatever reason Ocugen only gets valued at 4.5x yearly revenue well that puts their market cap at $18.5b and SP"
X Link 2024-09-29T17:15Z [----] followers, [----] engagements
"$ocgn shocking who would have thunk it https://www.trialsitenews.com/a/breakthrough-emory-researchers-find-covid-19-mrna-vaccines-fail-to-prompt-long-term-antibodies-b210949b https://www.trialsitenews.com/a/breakthrough-emory-researchers-find-covid-19-mrna-vaccines-fail-to-prompt-long-term-antibodies-b210949b"
X Link 2024-09-30T11:18Z [----] followers, [----] engagements
"Today Im sharing my theory of everything. When Im not deep diving into stocks Im often lost in the mysteries of the cosmos. One of the most fascinating puzzles for me Quantum mechanics. After years of pondering I think I might be onto something. My theory challenges the core ideas of the quantum realm but Im not claiming proof experiments need to be done and Ive laid out how. Heres the kicker: a time-uncertainty principle. Time is fluid. Click the link to this rabbit hole if you dare🤓😉 https://mytheoryofeverything.tiiny.site https://mytheoryofeverything.tiiny.site"
X Link 2024-10-12T00:26Z [----] followers, [----] engagements
"$ocgn Time to fast track Ocu520"
X Link 2024-10-16T12:52Z [----] followers, [----] engagements
"$ocgn good Ocu410 data would imply a lot more than a potential cure for a disease effecting millions. It solidifies the deal Ocugen has to offer and a partnership that includes territorial rights for Ocu400 the next cure for RP and Ocu410 a potential cure for Geographic Atrophy(GA) thats phase three ready is a deal worth well over a billion dollars. A phase [--] gene therapy for GA sold for $1.5b in [----] but failed its phase [--] September [----]. 🔜💸 🏦👽"
X Link 2024-10-18T01:19Z [----] followers, [----] engagements
"You bring up a good point but theres grey areas on whats considered material and we fall directly in this area. For early phase trials like Phase 1s companies have flexibility regarding the timing of the trials progression. Also Ocugen will know how their drug is progressing well before the trial formally concludes. For example Shankar mentions that Ocu410s safety interim results are coming soon and how theres global interest in them. Companies are not required to publicly disclose good interim safety reports within [--] days this is not counted as material information and is considered part of"
X Link 2024-10-18T22:55Z [----] followers, [---] engagements
"Early on during the pandemic US sent their top team of scientists to Wuhan to figure out its origins. Anyways after scientists spent a week there I just happened to be listening to NPR and heard there report live. They said it came from a lab and NPR asked them how sure and they responded 99.8% sure and they cut the broadcast immediately. Following this was nonstop media coverage about the lab leak conspiracy and how it held no merit even though the report is on govs website and the conspiracy came from the top experts. I will never forget it was truly shocking to hear first hand."
X Link 2024-10-21T19:28Z [----] followers, [---] engagements
"$ocgn Know what you own because the current share price doesnt even come close to reflecting it. Retail isnt buying millions of shares daily smart retail has bought and is holding or continues to buy paycheck to paycheck and holding. Case in point: todays short volume was 1.84M shares making up 73% of the total volume and yet we only dropped 0.9%. 😂 So does 73% short volume mean that institutions are bearish on Ocugen Out of the [---] institutions that own Ocugen [---] of them are long only [--] have a long position with a short hedge and ZERO are short only. The bearishness here is just a fugazi."
X Link 2024-10-23T03:46Z [----] followers, [----] engagements
"$ocgn Been here since the company went public telling everyone not to fear a reverse split. My take faced a lot of criticism but I knew one would never happen given the fundamental structure. While others pushed fear I advised everyone to load up for the compliance push explaining how Q1 was the most likely time for it with nothing but big news set to follow. From $0.30 to over $1 we went achieving compliance late Q1. Now here I am again urging you all to prepare for the massive catalyst on the horizon. The coming week marks a major inflection point for Ocugen with Ocu410s Phase 1/2 data"
X Link 2024-11-07T23:58Z [----] followers, [----] engagements
"@JJRich59 They know when to play their cards and 🎯 the [--] tutes short on ocgn do it as a hedge with shares to cover/go long. Imo price will rise a good bit before management is awarded their vested fixed rate warrant compensation then perfect time for big news PR & rip retail shorts 😂"
X Link 2024-11-08T04:31Z [---] followers, [---] engagements
"$ocgn oh am I excited about this clinical showcase next week. This data has to be really good showcasing the efficacy results with the trial participants there in the flesh. Big Pharma has sought a Geographic atrophy drug for decades. Will become an instant blockbuster with a market in the millions. Bask in the sp absurdity do as big money is doing and load up on the next Big Pharma company before anyone realizes what they have accomplished and own. This is beyond an obvious win fam capitalize 🐂"
X Link 2024-11-08T22:42Z [----] followers, [----] engagements
"$ocgn Great to see the @US_FDA s Guidance for Industry prioritizing gene therapy acceleration for rare diseases and unmet medical needs. [--] in [--] people reading this will face a condition without approved treatments. With guidelines like these gene-agnostic drugs full potential can be unlocked bringing hope back to millions. with a quicker less risky path to market companies can finally explore all possible markets for a drug instead of just the most profitable ones. #OCUGEN #OCU400 #OCU410 #ICU410ST .really interesting stuff it is about [--] pages but I post the most interesting ones in my"
X Link 2024-11-10T21:09Z [----] followers, [----] engagements
"@RobertKennedyJr Absolutely just look at the way Fauci handles this question. From media pumping agendas to government officials selling us products they get kickbacks from with sales funded by taxpayer dollars. The propaganda is heavy and beyond obvious. Get them snakes RFK good luck"
X Link 2024-11-11T01:57Z [----] followers, [----] engagements
"$ocgn stellar data and showcase inbound Lesgo 🐂"
X Link 2024-11-11T20:13Z [----] followers, [----] engagements
"we spent at LEAST $15m the last two years to protect this POS while @RobertKennedyJr was denied gov security [--] times as a presidential candidate. Fauci a private citizen who made millions off mRNA kickbacks from sales funded by taxpayers is still freeloading off us. 🤦♂"
X Link 2024-11-12T00:06Z [----] followers, [----] engagements
"$ocgn absolutely incredible couldnt ask for better results. This data represents hope for millions around the world. 🤯 Big Pharma look out 😜 🚀"
X Link 2024-11-12T18:15Z [----] followers, [----] engagements
"@Jzy8902 Not even counting Stargardt NeoCart and Next Gen vaccines too. 🤯💸 🏦"
X Link 2024-11-13T14:02Z [----] followers, [---] engagements
"$ocgn just a friendly reminder to know what you own because the people below sure as shit know what their buying. 😉🍻"
X Link 2024-11-14T00:06Z [----] followers, [----] engagements
"$ocgn its that easy. 🐂"
X Link 2024-11-14T18:02Z [----] followers, [----] engagements
"$ocgn nice 😎 Dr. Huma Qamar Chief Medical Officer at Ocugen shared her insights on managing complex gene therapy trials to ensure quality and consistency in patient care with @ClinicalLeader1 and @_CellandGene To read the full article click here: https://t.co/6zcBLhTocC Dr. Huma Qamar Chief Medical Officer at Ocugen shared her insights on managing complex gene therapy trials to ensure quality and consistency in patient care with @ClinicalLeader1 and @_CellandGene To read the full article click here: https://t.co/6zcBLhTocC"
X Link 2024-11-16T19:00Z [----] followers, [----] engagements
"@crisis_parade @DaniBeckman Me 😎"
X Link 2024-11-16T19:36Z [----] followers, [---] engagements
"@crisis_parade @DaniBeckman Thanks not on Spotify to my knowledge I made a playlist on SoundCloud though that has most of my songs. 🍻 https://on.soundcloud.com/dmJ2VWjiBXRUDLQZA https://on.soundcloud.com/dmJ2VWjiBXRUDLQZA"
X Link 2024-11-16T20:14Z [----] followers, [--] engagements
"$ocgn say whaaat 😲🤯"
X Link 2024-11-18T13:54Z [----] followers, [----] engagements
"$ocgn 💰🐂🐂🐂 https://ir.ocugen.com/news-releases/news-release-details/ocugen-announces-compelling-preliminary-data-ocu410-single-dose/ https://ir.ocugen.com/news-releases/news-release-details/ocugen-announces-compelling-preliminary-data-ocu410-single-dose/"
X Link 2024-11-19T12:29Z [---] followers, [----] engagements
"$ocgn Wow Listening to the patients just made my day 🥲 ❤ Theres no better feeling than making money while changing the world for the better. These drugs just revolutionized the gene therapy industry. A one shot solution to countless diseases bringing hope back to millions. Were at the forefront to a new age in healthcare. What an incredible time to be invested. 🍻"
X Link 2024-11-20T20:31Z [---] followers, [----] engagements
"$ocgn got friends in high places"
X Link 2024-11-21T01:55Z [----] followers, [----] engagements
"$ocgn soon to be leaders in the gene therapy industry. 🐂"
X Link 2024-11-26T13:24Z [---] followers, [----] engagements
"$ocgn were at [---] institutional owners now lol. To the retail getting robbed before our rise I tried to warn you. 😂 💀 To the ones who know what you own exciting times ahead. 🍻"
X Link 2024-11-27T20:17Z [---] followers, [----] engagements
"$ocgn comprehensive value analysis of a BP partnership catalyst. You know what I expect but what value do you see coming to Ocugen near term(1 year) to long term(2-5 years)"
X Link 2024-12-09T02:10Z [---] followers, [----] engagements
"$ocgn 🔥👏 https://finance.yahoo.com/news/data-safety-monitoring-board-reviews-113800039.html https://finance.yahoo.com/news/data-safety-monitoring-board-reviews-113800039.html"
X Link 2024-12-19T13:08Z [---] followers, [----] engagements
"@RobertKennedyJr @MartyMakary @elonmusk @realDonaldTrump You guys must put a stop to this madness. Our health agencies scientists and Big Pharma are laundering billions of taxpayer dollars. They spend enormous sums on a single platform that will never eradicate infectious diseases while actively blocking market access for platforms that could. Theyre selling the public misleading data and false hope lining their pockets as billions are wasted. This platform only mimics a small part of viruses famously studied for their high mutation rates. Its efficacy is short lived and plummets when"
X Link 2024-12-23T22:23Z [---] followers, [----] engagements
"@amldean19 @RobertKennedyJr @MartyMakary @elonmusk @realDonaldTrump 😂 🙏"
X Link 2024-12-24T01:17Z [---] followers, [--] engagements
"$ocgn hint smart money buys before approval. Youre welcome. 😉🍻"
X Link 2025-01-02T06:46Z [---] followers, [----] engagements
"$ocgn key things to note. Ocu410s phase [--] has [--] participants just 1/5 the size of typical gene therapy trials for geographic atrophy (GA) . 255-365 participants). This suggests the FDA has significant confidence in OCU410s safety and its mechanism of action in reducing lesion growth in GA patients based on promising Phase [--] results. Phase [--] dosing is expected to complete early this year followed by 9-12 months of efficacy updates measuring lesion growth and visual acuity improvements. Ocugen has been working closely with the FDA to potentially structure this Phase [--] trial as a Pivotal trial."
X Link 2025-01-06T23:54Z [---] followers, [----] engagements
"$ocgn look at the trial results below. While other gene therapies targeting single mutations are being bought for billions we own a drug that corrects over [---] mutations. For the first time in history humanity has unlocked the master regulators of genetics allowing us to cure countless diseases with a single breakthrough. You move methodically after unlocking the new frontier of Gene Therapy patients pays ten fold here. 🍻"
X Link 2025-01-15T14:47Z [---] followers, [----] engagements
"$ocgn I think LFG and its about damn time. @NIH @BARDA @Ocugen The data is clear: the Viral Vector platform is designed to outperform others for pandemic preparedness especially as a mucosal vaccine against respiratory viruses. The few hurdles listed associated with Viral Vectors are overcome using ChAd vectors. This technology has already proven itself overseas with millions of doses administered as a mucosal vaccine. Providing long lasting protection while only using a fraction of the drug substance compared to intramuscular vaccines. Americans are fortunate that a U.S. based company owns"
X Link 2025-01-17T22:45Z [---] followers, [----] engagements
"$ocgn Psst hey you yes you follow me I wanna show you something. See the list below Its a list of every expedited approval that happened in [----]. Impressive Sure. But heres the fun part I went ahead and analyzed each one and compared it to Ocu400. What I found is simple: OCU400 doesnt just stack up against these its in a league of its own. Efficacy safety unmet needs you name it OCU400 dominates the board. These other drugs earned early FDA approval but they dont even come close to what Ocugen has delivered. 100% efficacy mutation agnostic design zero serious adverse events and the cure to"
X Link 2025-01-19T05:06Z [---] followers, [----] engagements
"Somewhat cash strong with runway to [----] and lines to get debt financing. Management ownership is all tied up in vested fixed rate warrants and company continues to expand their heavy hitting pipeline so well be looking at partnerships for Ocu400/410 not buyout. Vid shows Shankar talking about when theyll look at the partnership offers note they received non dilutive funding after this conference. Imo even if Ocugen has all the financing they need to go commercial alone well still see partnership happen likely with a company who has a global infrastructure footprint like Novartis. Takes time"
X Link 2025-01-19T23:05Z [---] followers, [---] engagements
"$ocgn it will be interesting to see what happens after the purge of incentivized corruption and the scientific playing field is leveled. Ocugen truly owns the best platform to prepare for infectious diseases especially respiratory ones with our advanced delivery systems. Shankar was one of the creators and lead the most successful global vaccine launches in history which gave Pfizer their number [--] most lucrative cash cow of all time. No one in this field has a more proven track record than him. With an even playing field the competition is miles behind. The innovations we bring will"
X Link 2025-01-28T17:59Z [---] followers, [----] engagements
"$ocgn Ocufam our time is finally coming. Why would Ocugen clear its debt and free up patent rights patents that had to be unrestricted for any partnership Which company just said theyd be reviewing all partnership agreements in Q1 Yup 🍻"
X Link 2025-02-01T00:00Z [---] followers, [----] engagements
"@catalyst_i Idk may be worth the look. I remember thinking the same with Bluebird Inc after approval for sickle cell. Turns out another drug Casgevy by Vertex Pharmaceuticals was approved same day and priced $1m cheaper($2m) than Bluebirds($3m). Vertex Casgevy sales beat expectations. 🍻"
X Link 2025-02-06T14:36Z [---] followers, [--] engagements
"$ocgn The real reason for Ocugens incredible discount after multiple trial results showing they possess the cure for blindness Retail doesnt comprehend it. The vast majority of retail money moving daily comes from day traders chasing hype trying to make a quick buck. Ocugen doesnt appeal to that kind of money pre revenue so no ER to pump R&D cash burn and products that only real investors care about. Big money is buying for the substance they hold control of our day to day SP hence why we see over 70% of daily volume trading through dark pools. They own the price action until news drops that"
X Link 2025-02-14T17:56Z [---] followers, [----] engagements
"$ocgn If you're investing do it for the catalysts not the day to day stock price. This is an extremely undervalued biotech with a pipeline that justifies a valuation closer to $10 billion than $100m. Management's incentives are aligned with shareholders here with most of their ownership tied to vesting fixed rate warrants. For example the majority of the CEO's ownership consists of warrants(right to buy shares at a later date) with a fixed(at a fixed price) exercise price of $1.25 which won't fully vest(become available) for another two years. So management incentives are focused on building"
X Link 2025-02-24T13:41Z [---] followers, [----] engagements
"$ocgn this is huge 🔥 https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-announces-fda-alignment-phase-23-pivotal-confirmatory https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-announces-fda-alignment-phase-23-pivotal-confirmatory"
X Link 2025-02-27T14:05Z [---] followers, [----] engagements
"$ocgn Ocu410ST [--] subjects [--] of whom will receive Ocu410ST One year data will be utilized for the BLA filing. 💥 🏦 💸 💸 🐂 $ocgn even though most of the market hasnt the faintest clue what a pivotal trial means I cant stop thinking about another product coming to market after a trial with just one year end points and needed to share it. Blockbuster after blockbuster. 🍻 https://t.co/wtYMWN6EsM $ocgn even though most of the market hasnt the faintest clue what a pivotal trial means I cant stop thinking about another product coming to market after a trial with just one year end points and"
X Link 2025-02-27T14:30Z [---] followers, [----] engagements
"$ocgn Ocugen filed a patent for a Multicistronic vaccine on February 13th. Multicistronic meaning the vaccine encodes at least two different antigens (influenza and COVID-19) aka Ocu520 our two in one Covid+flu vaccine. Now ask yourself why is Ocugen expanding their next Gen vaccine platform when govs in the middle of testing just their Covid vaccine Hint hint. 🍻"
X Link 2025-02-27T20:15Z [---] followers, [----] engagements
"$ocgn first partnership then pipeline explosion acquisitions and global expansion. We'll see Ocugen at all systems go towards their journey to becoming one of the giants in pharmaceuticals. Then revenue and insane profit margins think Novartis with extra billions in cash on hand each quarter. This is the start of a global takeover priced at $189m lol. No 🧠er💥🚀"
X Link 2025-03-03T03:51Z [----] followers, [----] engagements
"Novartis owns Luxturna the first gene therapy approved for RP which fixes one mutation responsible for 0.5%-1.5% of RP patients. Ocu400 is gene agnostic and will take over 50% of the market. Novartis also bought a Phase [--] gene therapy for GA for $1.7B but it failed Phase [--] and a week later Ocugen started dosing Ocu410 for Phase [--]. Novartis also sold their entire stake in Roche and is in the market for new drugs and partnerships. Ocugen already has its own cGMP manufacturing in the US while Novartis has extensive infrastructure in regions heavily impacted by inherited eye disease like MENA"
X Link 2025-03-03T12:34Z [---] followers, [---] engagements
"$ocgn same cycle same noise same outcome. Load the boat. 🍻"
X Link 2025-03-06T02:20Z [---] followers, [----] engagements
"@BrauneArno Yeah but still Novartis is a much more likely pick to partner for Ocu400/410 imo 😉 🍻"
X Link 2025-03-17T22:56Z [----] followers, [---] engagements
"$ocgn getting spicy over here 🐂"
X Link 2025-03-21T13:31Z [----] followers, [----] engagements
"$ocgn is the highest ranking pure biotech on this highest off exchange [--] day trading volume list. First we saw heavy short interest Then dark pool volume surge Next cost to borrow rate spiked Now the price is steadily rising without any insane volume or retail FOMO To me it looks like big players are accumulating anticipating a catalyst. They buy off exchange to avoid spiking the SP but this also pulls shares out of circulation. Less shares circulating means borrow fees go up which in turn puts pressure on the price to rise. Big PR is on our horizon imo. 🍻"
X Link 2025-03-26T12:05Z [----] followers, [----] engagements
"$ocgn Since the dawn of man vision loss in RP Stargardt LCA and dry AMD was inevitable. Once these diseases took hold a patients only option was to wait and watch as the light faded to black. But Ocugen said f*ck that reality and now for the first time in human history the future shines bright for millions around the world. Ocugen just added more updated data to their ever growing list of banging trial results. Data showing that treated eyes in the OCU410 dry AMD trial didnt just stabilize they gained nearly [--] lines (23 letters) of vision compared to the untreated eye. Thats no fluke. Thats"
X Link 2025-04-04T23:30Z [----] followers, [----] engagements
"$ocgn is the most discounted biotech on the market 💯 and heres why. In [----] investments in cell and gene therapy surged to $15.2 billion a [--] percent jump from the year before. But if you looked at Ocugen alone youd never guess it. The market at large doesnt grasp the complexity behind these next gen therapies. Were talking about correcting specific gene mutations to treat small subsets of patients. Thats a whole lot of variables for retail. And lets be real most people arent nerds like me 🤓. They dont have the time to look at the science and figure out what really separates one therapy"
X Link 2025-04-08T13:38Z [----] followers, [----] engagements
"Novartis has spent billions trying to carve out a foothold in the retinal gene therapy space capturing just 0.5% to 1.5% of the RP market with Luxturna and attempting to enter the massive GA market through GT005. Theyve also invested heavily in building out global infrastructure particularly in regions like the Middle East where inherited diseases are most prevalent. Ocugens drug OCU400 is designed to treat the majority if not all of the RP/LCA market. And their GA drug OCU410 began dosing for its Phase [--] trial just one week after Novartis announced it was discontinuing development of GT005"
X Link 2025-04-13T00:13Z [----] followers, [--] engagements
"$ocgn why buy Ocugen You gonna wish you did. 🍻 💸 🏦 🐂"
X Link 2025-06-02T13:40Z [----] followers, [----] engagements
"$ocgn this also includes a supply agreement "Ocugen will manufacture commercial supply of OCU400 under terms of a supply agreement.". That means Ocugen earns revenue from two streams: 25% royalty on net sales (huge by industry standards). Profit from manufacturing and supplying the product (likely adds 30-50% margin). $11M in upfront and near-term payments $1M for every $15M in net sales up to $150M+ in the first [--] years. So this isn't just a royalty stream it's: Guaranteed near term cash a built in reward system as Korean partner scales sales Control over manufacturing which keeps quality"
X Link 2025-06-05T13:48Z [----] followers, [----] engagements
"The $200 trillion is not liquid thats the gross national household net worth estimate. Talking private property homes retirement accounts stock holdings family businesses land art and not government owned. What is the suggestion here nationalizing private wealth My god were all cooked fam. Theyd rather come up with some scam than even attempt to balance the budget. Sovereign Wealth Funds only work with surpluses. You invest the excess revenue to generate returns or in this case pay off debt. The problem is we dont have a surplus. We have a $1.7T deficit and were borrowing just to pay the"
X Link 2025-06-07T02:13Z [----] followers, 32.7K engagements
"$ocgn you ever watch a stock go from spare change to double digits then triple Keep your eyes on Ocugen over the next [--] years youll see. The next big pharma is making its debut. 🍻 https://www.globenewswire.com/news-release/2025/06/11/3097456/0/en/Ocugen-To-Present-at-BIO-International-Convention-2025.html https://www.globenewswire.com/news-release/2025/06/11/3097456/0/en/Ocugen-To-Present-at-BIO-International-Convention-2025.html"
X Link 2025-06-11T14:58Z [----] followers, [----] engagements
"@BAMBossie81 Yes and I love the idea spin offs are a great way to see value from a product thats overlooked by the market. It also acts like a buffer from negatives that may come like big R&D costs and lower sales. Ocugen can see the value Neo deserves without the risks to their books"
X Link 2025-06-19T00:04Z [----] followers, [---] engagements
"@MoreFlax Ocu200 is a tumortargeting fusion protein (tumstatin + transferrin). Imo that news has always been coming but now Idk 🤷♂ could also be a typo 😆"
X Link 2025-06-20T03:59Z [----] followers, [---] engagements
"$ocgn When the merged company lists under a new ticker nothing changes for Ocugen holders we still own 90% of it. The new ticker just represents the public float (the other 1015%). If you already hold Ocugen you already own most of the new company. The easiest way to think about it is: Ocugen now owns a new asset. So if CARM trades at a $1B valuation Ocugen holds 8090% of that meaning weve got an $800900M asset sitting on our books. @NattaCop what happens when they list the new ticker for the merged company @NattaCop what happens when they list the new ticker for the merged company"
X Link 2025-06-23T15:27Z [----] followers, [----] engagements
"$ocgn Guys this is 100% a good deal a spin off is clever but isnt anything crazy or super hard to comprehend. The only way this wouldnt be a good deal is if you think Ocugens SP had NeoCart value significantly baked into its SP already and losing that 10% will hurt out bottom line. Fact is NeoCart was extremely overlooked by the market and our SP didnt reflect the value at all. Now this neglected asset will receive its true value and Ocugen gets to reap the benefits by having that now valuable traceable asset on our books and an early source of manufacturing revenue. If you wanted to fund"
X Link 2025-06-23T16:51Z [----] followers, [----] engagements
"Hence why I mentioned [--] to [--] percent. The [--] percent figure is before the funding. After the [--] million raise it drops slightly but that dilution covers the entire Phase [--] push without touching Ocugens balance sheet. We still own the majority control manufacturing and hold an asset that can grow independently while reflecting directly as value on our books. Thats the entire point. Risk is offloaded upside is kept"
X Link 2025-06-23T19:51Z [----] followers, [---] engagements
"Ive followed this product for over [--] years and I believe the value goes well beyond that. The upcoming trial is structured for approval. The last one failed due to one outlier group extremely thin patients with the smallest micro lesions. That group has been removed from the new Phase [--]. The market is massive and NeoCart with RMAT status and set for early access is positioned to become the new standard of care. The data speaks for itself. 🥂"
X Link 2025-06-23T20:37Z [----] followers, [---] engagements
"The [-----] percent ownership figure is based on a conservative $110 million valuation for Ocugens NeoCart asset. But that number only holds if the $20 million being raised is priced at that same valuation. In reality the final ownership percentages will depend on how the market values the new company when it lists. If demand is strong and the market values NeoCart and the merged entity above $110 million then investors putting in $20 million will receive a smaller percentage of the company and Ocugens ownership will end up higher than [-----] percent. At the end of the day the market has the"
X Link 2025-06-23T21:34Z [----] followers, [---] engagements
"Theres zero dilution of Ocgn shares from this merger. Ocugen didnt issue new stock it spun out OrthoCellix retained majority ownership of a new public company without burning any cash. If youre saying thats dilution you dont understand the deal. Show grok if you can the filing itself or screenshots then ask it. Or just read the filing yourself it really isnt too complicated. 🍻 https://www.streetinsider.com/dr/news.phpid=24962186 https://www.streetinsider.com/dr/news.phpid=24962186"
X Link 2025-06-23T21:53Z [----] followers, [--] engagements
"No it doesnt you tagged grok under a post with the most dog water take Ive ever seen. @grok analyze this link people are claiming that Ocugen shareholders are getting their shares diluted through this deal but theyre clearly confused. Explain why this deal doesnt dilute Ocugen shareholders and why its a bullish deal for Ocugen shareholders. https://www.streetinsider.com/dr/news.phpid=24962186 https://www.streetinsider.com/dr/news.phpid=24962186"
X Link 2025-06-23T23:20Z [----] followers, [--] engagements
"@amldean19 @BAMBossie81 🎯 Fact nobody ever gives this much of a dog water take about a filing with this much conviction whos genuinely just confused. This guy swing trades and posts solely to manipulate people based on his trades"
X Link 2025-06-23T23:31Z [----] followers, [---] engagements
"$ocgn NeoCart is the perfect candidate for government funding. Military accelerates joint degeneration especially the knees. VA spends billions annually treating this damage. Knee injuries are among the top service connected disabilities for veterans. Neocart would save them billions of dollars since NeoCart cartilage implant is designed to regenerate making it a curative treatment that would drastically reduce future surgery rates and long term disability claims. The numbers dont lie. There are existing government initiatives under ARPA-H BARDA and MTEC focused on regenerative medicine and"
X Link 2025-06-25T18:12Z [----] followers, [----] engagements
"$ocgn little birdie says"
X Link 2025-06-30T21:41Z [----] followers, [----] engagements
"$ocgn https://ir.ocugen.com/node/13931/html https://ir.ocugen.com/node/13931/html"
X Link 2025-07-01T20:07Z [----] followers, [----] engagements
"$ocgn many are confused saying didnt we go [--] consecutive days above $1. Youre not crazy we did stay above $1 for what usually is required by NASDAQ. This is not a SEC rule though its not black and white like that. NASDAQs exchange their rules and their discretion. Ive seen NASDAQ grant us compliance with far less bullish news and closer to $1 closing days. This time was they wanted a little more for whatever reason. Important thing is we were granted the [---] day extension and have a mountain of good news on the way. This is not a problem for us we will be just fine. 💯 🍻"
X Link 2025-07-01T21:43Z [----] followers, [----] engagements
"$ocgn Inside the new spending bill is something called the Orphan Cures Act and it changes everything. Ocugens modifier corrects [---] mutations. These mutations dont just cause RP/LCA those are just the two biggest markets. In reality there are over [---] inherited retinal diseases in the U.S. with 5000+ patients tied to those mutations that Ocugens modifier platform could treat in the same exact way. Altogether it could potentially address 200+ inherited retinal diseases. Before this bill government policy actually punished companies for expanding into more than one rare disease. Doing so"
X Link 2025-07-02T07:34Z [----] followers, [----] engagements
"$ocgn Spend billions now to save hundreds of billions from being burnt yearly later. 🍻 $ocgn Inside the new spending bill is something called the Orphan Cures Act and it changes everything. Ocugens modifier corrects [---] mutations. These mutations dont just cause RP/LCA those are just the two biggest markets. In reality there are over [---] inherited retinal https://t.co/YZHLu7Xfv5 $ocgn Inside the new spending bill is something called the Orphan Cures Act and it changes everything. Ocugens modifier corrects [---] mutations. These mutations dont just cause RP/LCA those are just the two biggest"
X Link 2025-07-02T14:00Z [----] followers, [----] engagements
"$ocgn What a blessing for companies pursuing treatments for rare diseases and an even greater one for the millions of Americans currently suffering. This legislation is insanely valuable. Yes companies like Ocugen will profit immensely but so will the American people who are currently stuck paying over $900 billion each year due to the economic burden rare diseases place on society. 👏 🥳 @Ocugen . good for companies with Orthan drug including #OCUGEN $OCGN This will be epic for our full pipeline The Bill was passed Congratulations to all https://t.co/JT5ZXbe4k7 @Ocugen . good for companies"
X Link 2025-07-03T22:31Z [----] followers, [----] engagements
"$ocgn Luxturna corrects a single mutation and holds .5%-1.5% of the RP market. Encelto is holds 0% of the RP market. A implant approved for MacTel type [--] slows degeneration by 33% provides 0% visual gain. Lasts [--] years on average. An early study for RP was conducted showed no visual acuity improvement and recorded no measurable slowdown in degeneration. OCU400 will hold 70%+ of the RP market. It's a one shot cure with a gene agnostic mechanism of action that corrects 150+ gene mutations. Studies show 80% of patients with RP and LCA report visual improvements with gains of up to 3+ lines on"
X Link 2025-07-08T13:58Z [----] followers, [----] engagements
"$ocgn [--] BLAs each year for the next [--] years. Buy now or chase later. Also 🔥 post Ocugen 👏"
X Link 2025-07-10T18:39Z [----] followers, [----] engagements
"$ocgn Owning a breakthrough in healthcare before the world knows feels incredibly rewarding. Were on the verge of a one shot cure a lifeline for those suffering from diseases that steal the gift of sight from millions. And like Ive mentioned before this is only the beginning. Ocugens innovative modifier platform is a new approach and it redefines the entire industry its a revolutionary shift in how we typically combat these challenging genetic diseases. Theyre rewriting how we treat inherited diseases and the $50B+ market theyre stepping into wont look the same after. This is what a paradigm"
X Link 2025-07-10T19:40Z [----] followers, [----] engagements
"$ocgn The commercialization phase has begun. New VP Abhi Gupta helped build Pfizers $5.5B gene therapy portfolio led a 200+ global team at Syneos and held leadership roles at J&J and Regeneron. You dont bring in someone like that unless youre gearing up to go worldwide. 🍻"
X Link 2025-07-15T13:58Z [----] followers, [----] engagements
"$ocgn Were less than [--] days away from finding out who our Korean partners are. 🍻 $ocgn You know the product is good when you see regional deals like the Korean deal. Royalty percentage far above industry average retained manufacturing control strong upfront and milestone payments and companies are paying this premium for a market thats only [--] percent the https://t.co/uLMZkbwS0J $ocgn You know the product is good when you see regional deals like the Korean deal. Royalty percentage far above industry average retained manufacturing control strong upfront and milestone payments and companies"
X Link 2025-07-17T13:46Z [----] followers, [----] engagements
"$ocgn Some call the latest news fluff tossing wild takes like not relevant. They post nonstop about this stock but couldnt tell you what words like pivotal/Orphan/RMAT/or FDA reforms even mean. Most stare at charts all day role playing as biotech experts while billion dollar catalysts stare right at them. OCU410ST dosed its first patient in their pivotal Phase 2/3 trial. Pivotal = BLA can be filed right after if successful. Endpoints are [--] months only [--] patients and dosing has started. No approved treatment exists for Stargardt a disease blinding children. With orphan pricing ($1.25M$1.5M)"
X Link 2025-07-21T03:43Z [----] followers, [----] engagements
"$ocgn Luxturna treated 0.5% of the RP market thats a global population of under 10K patients. They still did $120M in year one got acquired for $1.4B then later bought by Roche for $4.8B for a one mutation product Now compare that to Ocu400/410/410ST which are gene agnostic and target broad IRD populations in RP GA and Stargardt. Just Ocu410ST alone is going after a market 30x50x the size Luxturna targeted Factor in FDA reforms cutting BLA reviews to [--] months orphan pricing now securing prices at $1.25M+ no matter how many diseases a drug treats and rewards like priority review vouchers that"
X Link 2025-07-21T20:18Z [----] followers, [----] engagements
"$ocgn Most people have never heard of Ocugen. Thats exactly why its a goldmine. This isnt some hyped up penny stock. Its a pre commercial biotech entering the revenue phase backed by real science and billion dollar catalysts the market hasnt priced in yet. They recently landed a global licensing deal for only 1% of their products target market that proved they can generate massive upfronts milestone payments royalties in perpetuity and manufacturing revenue without dilution. This deal gave Ocugen the cash runway to file BLA next year. One more deal like that and suddenly their cash runway"
X Link 2025-07-28T01:42Z [----] followers, [----] engagements
"$ocgn ahh the classic traders spamming outrage over ER lol. this pre revenue stock gets attacked every earnings ya its wild I know 🤪 anyways for any real investor 🙋♂ this is exactly what we wanted to see. all systems are go to bring blockbuster products to market back to back to back over the next [--] years. well soon learn who our well-established leader in pharmaceuticals in Korea partner is. look at that premium licensing deal 🤤 Stocks gonna make a lot of retail with foresight rich along with this all star management team whose incentives directly align with us. Ownership is tied to"
X Link 2025-08-01T23:20Z [----] followers, [----] engagements
"mRNA is the sole reason Americans are waiting for a pandemic vax at all. [--] years of blocking every traditional platform egg cell vector just to force mRNA to the front. Billions in taxpayer funds funneled into synthetic tech while proven paths were sidelined. NIAID and select insiders got kickbacks. Now they pretend theres no plan B out there. There was Until they buried it"
X Link 2025-08-05T23:41Z [----] followers, [----] engagements
"@RickABright Youve been involved with CEPI heres some data you helped surface that shows there are cheaper safer and still fast alternatives to mRNA. Platforms like viral vector tech are proven scalable and next Gen ready. Curious where you stand on these options now"
X Link 2025-08-05T23:48Z [----] followers, [----] engagements
"Lmao Im sure taxpayers love knowing they were guinea pigs so Big Pharma could test run their next cash cow all funded by public dollars sold back at a premium all while safer options were buried. NIH insiders got royalties Fauci cashed checks and now sleep soundly convincing themselves itll save lives in the long run. Reality is it cost countless ones"
X Link 2025-08-06T00:38Z [----] followers, [---] engagements
"No one denies mRNAs potential for gene therapy or future treatments. Thats not the conversation. Were talking about vaccines where Americans were forced into one rushed platform that failed to stop COVID cost more to produce store and deliver and left better options blocked. Taxpayers got scammed insiders got rich and pharma funneled billions while Americans died waiting for alternatives that were never given a chance. If youre saying all thats justifiable because mRNA might someday treat cancer cool. Lets talk. Odd they didnt fund it for that purpose from the start imo"
X Link 2025-08-06T00:50Z [----] followers, [---] engagements
"mRNA isnt proven safe it failed to stop transmission required endless boosters and had higher adverse events like myocarditis. Viral vector clotting issues were tied to specific formulations and injection routes not the platform. Next-gen mucosal viral vector vaccines avoid that entirely its not even injected. CEPIs own data proves theyre fast scalable and effective"
X Link 2025-08-06T00:59Z [----] followers, [--] engagements
"Call me fucking stupid Youve been pushing pharma dogma for years claiming mRNA has zero safety concerns. Pfizer doesnt even back you their own trial data showed tens of thousands of serious adverse reactions and over a thousand deaths. Thats why they fought to hide it for [--] years. You didnt see a loved one drop dead after the shot. That doesnt make you informed doesnt make you right just lucky and dangerously fucking stupid. https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf"
X Link 2025-08-06T01:36Z [----] followers, [---] engagements
"Novavax was sidelined for years just like other traditional options like Covaxin while the gov funneled billions into mRNA and forced it down Americans throats until 80%+ had already taken it. Only after that did Novavax get approved but dont leave out a key fact. Its only approved for people who hadnt already taken mRNA. Thats less than 20% of the country. You think dropping an alternative years late restricted to a sliver of the population shows a fair market"
X Link 2025-08-06T01:48Z [----] followers, [---] engagements
"CEPIs own data shows other platforms like viral vector and protein subunit could reach human trials within roughly the same [--] week window after mRNA candidates were designed. Yet only mRNA got billions in funding and priority approval despite being FAR more expensive to manufacture requiring new ultra cold storage infrastructure nationwide expiring multitudes faster and offering short lived non sterilizing immunity. Meanwhile the cheaper proven platforms with room temp stability and proven long term durability were sidelined. All this for a few weeks of speed That not science bud. Thats"
X Link 2025-08-06T02:18Z [----] followers, [---] engagements
"Market hasnt priced in any of these catalysts yet. Right now were a pre rev bio with the cash to get us to BLA next year but not all the way to commercialization/revenue. The market reads that as dilution ahead and values us like it. Theyre looking at it broadly they dont know managements incentives are tied to fixed rate warrants meaning their upside only comes if the stock goes up. Reality is if youve done the research management will avoid major dilution because it directly benefits them. The company has already shown they can bring in cash by other means partnerships with big upfronts non"
X Link 2025-08-07T23:54Z [----] followers, [---] engagements
"No Return Ticket https://on.soundcloud.com/HrQV6kbdE0WfBieWU3 https://on.soundcloud.com/HrQV6kbdE0WfBieWU3"
X Link 2025-08-08T01:53Z [----] followers, [---] engagements
"$ocgn I hear about products all the time and often theyre brought up because people view them as a threat to this companies pipeline. Sanofi's early stage Gene Therapy for Wet AMD being the latest. I like explaining why they are not because it shows exactly why what we own is special. So heres why it is silly to see Sanofis as a threat when it is actually the opposite. This is just one story but the ending mirrors all the others. Sanofis drug is just another anti VEGF product for wet AMD only trying to cut the amount of shot visits patients need. Its basically J&Js Covid vaccine DNA delivered"
X Link 2025-09-18T01:48Z [----] followers, [----] engagements
"@m3alaam The cure to blindness first of many partnerships announced Ocu400 will be in Korea. Deal has extremely bullish terms for us with a top [--] Korean pharma. My page is full of details about this stock. 🍻"
X Link 2025-09-18T19:11Z [----] followers, [---] engagements
"$ocgn 1st off fam winning feels good. Bears your Ls are stacking nice. Hows that subscription 😜 2nd see how non of these analysts know the damn price of our drug tossing numbers like $200K lol. The price is on Ocugen's slide these peeps are lazy and overworked. Writing analyst articles about a stocks product giving PTs and everything and they dont even know the price. 🤯🤦♂ And no he's not being conservative. $750K in EU and $850K US is the absolute floor $1.5m the ceiling. No pharma is spending tens of millions on R&D for a drug not knowing what insurers are willing to pay for it. This is"
X Link 2025-09-24T01:35Z [----] followers, [----] engagements
"$ocgn a stock question answer that shows why the fundamentals here = growth. 💸 🏦 Management owns a total of 4.51m right to buy fixed rate options that are mostly vested (around 500k fully vest in 2026). Shankar for example owns 1.475m fixed at $1.25 and he doesn't need to exercise them for another [--] years and [--] months. You'd want to wait as long as you possibly can for the highest SP to exercise them because that = more ownership for free. A stock at $100 means that every share bought at $1.25 gets you [--] shares for free that's 1.18m shares that are worth $118M for free. This fundamental"
X Link 2025-09-25T06:37Z [----] followers, [----] engagements
"$ocgn company has nothing but big news to announce for months and years to come. Easiest buy there ever was. 💸 🏦 🚀 🌙"
X Link 2025-10-02T15:56Z [----] followers, [----] engagements
"$ocgn Bullish trends meet news packed conferences and business updates. Got to love where this is heading 🤑 EZ 💸 🏦 🍻 Nothing like hanging out and talking about stocks. What nobody is talking about is the weekly 200MA. Thanks for pointing it out @Eduardo21881249 . https://t.co/OGtcem6Kll Nothing like hanging out and talking about stocks. What nobody is talking about is the weekly 200MA. Thanks for pointing it out @Eduardo21881249 . https://t.co/OGtcem6Kll"
X Link 2025-10-03T06:25Z [----] followers, [----] engagements
"$Ocgn This👇is what BARDA is looking for. Sound familiar"
X Link 2022-11-14T11:34Z [----] followers, [--] engagements
"$ocgn A revolutionary breakthrough in gene therapy. 👏"
X Link 2025-01-30T19:17Z [---] followers, [----] engagements
"$ocgn This is a critical part imo. The lenders hold a senior security interest in Ocugens assets including its intellectual property as collateral. This means that if Ocugen wants to license or transfer its IP it would need lender approval since the lenders have a lien on it. If a big pharma deal were negotiated and Ocugen sought lender approval it would make perfect sense for the lender to respond Well release the IP for licensing once you pay off the secured portion of the loan and wed gladly accept shares. This is what we witnessed imo"
X Link 2025-02-01T18:10Z [---] followers, [----] engagements
"$ocgn Oh is it nice to see validation catch up to very bullish speculation. Soon the biggest news in companys history drops. 🍻🚀🌙👽 $ocgn This is a critical part imo. The lenders hold a senior security interest in Ocugens assets including its intellectual property as collateral. This means that if Ocugen wants to license or transfer its IP it would need lender approval since the lenders have a lien on it. https://t.co/sMmeqTBXtH $ocgn This is a critical part imo. The lenders hold a senior security interest in Ocugens assets including its intellectual property as collateral. This means that"
X Link 2025-02-08T00:46Z [---] followers, [----] engagements
"$ocgn 🐂 https://www.investing.com/news/analyst-ratings/ocugen-shares-rise-as-hc-wainwright-lifts-price-target-to-8-93CH-3867565 https://www.investing.com/news/analyst-ratings/ocugen-shares-rise-as-hc-wainwright-lifts-price-target-to-8-93CH-3867565"
X Link 2025-02-13T16:30Z [---] followers, [----] engagements
"$ocgn Next Big Pharma 💯 🚀"
X Link 2025-02-18T14:36Z [---] followers, [----] engagements
"$ocgn soon well learn who our partners are in Korea. The Korean deal conservatively projects $2.19b in total manufacturing revenue with $506m in profit after treating half of Koreas RP market (7500 patients). Even at just 3% yearly market capture (of [----] patients) Ocugen would still generate $65.8m/year in manufacturing revenue for Korea alone. Now add $2b+ in royalties (of [----] patients treated) plus millions in milestone payments. Whats the value of a deal like this with a company that will have no problem executing it Imo Id value it with more confidence. 🍻"
X Link 2025-07-31T01:26Z [----] followers, [----] engagements
"$ocgn FDA is opening the door for rare disease CGT (Cell and Gene Therapies) with self controlled trials external controls and registry follow up saving years and millions in development. This directly accelerates OCU400 and OCU410ST bringing them to market at record speed 🍻 #OCUGEN $OCGN.rare disease designation 👇👇👇👇 https://t.co/VggIqSNwpu #OCUGEN $OCGN.rare disease designation 👇👇👇👇 https://t.co/VggIqSNwpu"
X Link 2025-10-03T21:42Z [----] followers, [----] engagements
"$ocgn Very interesting Job description specifically: in-plant leadership for manufacturing at Ocugen technical expertise and leadership to Ocugens external manufacturing partners lead technology transfers collaborate across the network This screams a hub and spoke model. Ocugens Malvern facility being the hub that runs the playbook and launch supply. Future partners are the spokes via tech transfer. Yet the only public partner so far is Korea where Ocugen keeps manufacturing control. For India my pick is Bharat Biotech. They have growing CGT capacity so that deal likely trades local"
X Link 2025-10-04T13:39Z [----] followers, [----] engagements
"$ocgn Company has the drugs the expertise and a way to cross the blood brain barrier. As an early backer betting on a revolutionary concept Ive watched this modifier gene approach reshape the gene therapy landscape and how we tackle rare diseases. With concept now a reality does the future stop at rare diseases Not even remotely close. This is the start of a paradigm shift in healthcare. The days of bandaid subscriptions are ending and the age of real cures is coming. Practically everyone has been or will be affected by diseases like Alzheimers Parkinsons autism etc. The question isnt if this"
X Link 2025-10-08T00:51Z [----] followers, [----] engagements
"$ocgn Most will see Phase [--] for GA in [----] and shrug. The ones who know GA the therapy and this market understand the gravity of what was just announced. Dr. Jay Chhablan the Vice Chair of Clinical Trials at the University of Pittsburgh Medical Center Vision Institute just said the [--] month OCU410 data already looks superior to the FDA approved drugs when he compared them side by side. Retail needs to understand why this sets OCU410 up as one of the most valuable medicines ever lined up to hit the market. Why Im saying that OCU400 family keeps winning. OCU400 for IRDs OCU410ST for Stargardt"
X Link 2025-10-13T13:40Z [----] followers, [----] engagements
"$ocgn breakthrough therapy after therapy continues to get nothing but stellar trial results. This will be the biggest pharma in the world. 💯 📠"
X Link 2025-10-15T21:40Z [----] followers, [----] engagements
"$ocgn like a glove 🍻 FDA will be proactive in advancing decisions on medicines serving a key national priority: affordability domestic production or meeting an unmet public health need. https://t.co/oUuEsAnBQ2 FDA will be proactive in advancing decisions on medicines serving a key national priority: affordability domestic production or meeting an unmet public health need. https://t.co/oUuEsAnBQ2"
X Link 2025-10-16T21:34Z [----] followers, [----] engagements
"$ocgn welcome @drsmusunuri biotech GOAT. May more see just how much brighter youre making the world. 🍻"
X Link 2025-10-17T17:03Z [----] followers, [----] engagements
"$ocgn Company Galactic 🤣 ☠"
X Link 2025-10-17T17:55Z [----] followers, [----] engagements
"$ocgn couldnt ask for better results. 🍻🔥"
X Link 2025-10-18T07:08Z [----] followers, [----] engagements
"🧵 $ocgn Hot take: stocks push to $2.5 will be followed by a Japan partnership announcement and Astellas clearly looks like the partner. Why Astellas"
X Link 2025-10-18T23:47Z [----] followers, [----] engagements
"Astellas is built for retina after the Iveric deal. Huge Japan field force. Real PMDA muscle. No RP conflict of interest. They know pricing and access and they move paperwork fast. How does Japans market look"
X Link 2025-10-18T23:47Z [----] followers, [---] engagements
"Use Korea as the benchmark. Korea deal was about 7.5M upfront with [--] percent royalties and Ocugen supplying drug. Scale by market size plus Japan pricing power and the math gets spicy. Spicy"
X Link 2025-10-18T23:47Z [----] followers, [---] engagements
"My range for a Japan only license Worst case 25M to 45M upfront Base 50M to 80M upfront Stretch 90M to 120M upfront Royalties [--] to [--] percent Ocugen likely keeps manufacturing on a cost plus margin. Math check"
X Link 2025-10-18T23:47Z [----] followers, [---] engagements
"Quick math check Assume bilateral price in Luxturna class. Treat [---] to [---] patients per year as capacity ramps. That is roughly 15B to 70B in yearly net sales. About 100M to 470M dollars at simple FX. At [--] percent royalty that is 20M to 100M a year to Ocugen before any supply margin. Speed"
X Link 2025-10-18T23:47Z [----] followers, [---] engagements
"Why Japan can move fast PMDA can accept foreign clinical data under ICH E5. Examples: Luxturna and Zolgensma. No need to redo the world. Our package fits that playbook"
X Link 2025-10-18T23:47Z [----] followers, [---] engagements
"Bottom line If Astellas takes Japan the package lands at a 3x to 6x multiple of Korea with double digit royalties and Ocugen keeping the manufacturing lever. This deal is going to be so f**king 🔥😉🤑 Do you Im am long. 🍻"
X Link 2025-10-18T23:47Z [----] followers, [---] engagements
"$ocgn Why build an AI team in India Because Ocugens gene agnostic platform has shown it can correct over [---] mutations. Recent FDA and global moves let platform therapies expand into related mutations or indications without a brand new BLA or new pricing negotiation. Many drugs could treat more but the risk stopped companies from trying. That barrier is gone now. For a platform that addresses over [---] mutations across multiple diseases this opens a path to reach millions who have nothing today. AI will help companies map the addressable markets design smarter trials and process the data at"
X Link 2025-10-21T04:22Z [----] followers, [----] engagements
"$ocgn very few understand yet but it will be very apparent to everyone soon. 🍻"
X Link 2025-10-24T02:38Z [----] followers, [----] engagements
"$ocgn If you are invested or thinking about it watch the latest panel discussion with the CEO Shankar. You have to fill your name and email and then the video will pop up. Its 40mins+ long but very worth the watch. Any investor or potential investor who watched this would put their money on Ocugen. While everyone else is focused on small progress Ocugen is focused on a paradigm shift and their drugs have proved that theyre just that. Basic summary: Others talked about how there's plenty of room currently in the market for other treatment options that they see commercial success for drugs that"
X Link 2025-10-26T00:34Z [----] followers, [----] engagements
"$ocgn New peer reviewed paper on OCU400: Perfect safety Vector stays in the eye no anti NR2E3 issues NR2E3 expression holds This paper de risks our BLA and sweetens the math for partnership. Bullish sentiment tailwind inbound I think so. 🍻"
X Link 2025-10-29T21:45Z [----] followers, [----] engagements
"$ocgn this stock is considered too risky in the eyes of big money and institutions. With phase [--] trials ongoing these major funds will wait until more data/BLA before investing. For retail who actually follow the pipeline have watched trial after trial get stellar results of 100% safety and 100% efficacy. When data rolls in analysts have to do real math. Weve already seen $8+ SP targets with most modeling 100k pricing. Our product and Gene therapy comps in general will live around $850k to $1.25m. First drug to market is for Retinitis Pigmentosa. Hundreds of thousands of patients worldwide"
X Link 2025-11-03T19:39Z [----] followers, [----] engagements
"$ocgn Exactly the update I wanted to see. OCU400 set to start a rolling BLA in 1H [----]. OCU410ST 50% enrolled and on track for a 1H [----] BLA filing. Cash on hand extends into [----] if Aug warrants are fully executed. EMA/CHMP accepted a single U.S. trial for the Stargardt MAA. Korea license for OCU400 reiterated $7.5m upfront milestones structured as $1.5M per $15M of sales(projecting $180M+ in first [--] years off milestone payments) 25% royalties and Ocugen supplies drug (keeping manufacturing control). OCU200 enrollment targeted to complete 4Q [----]. OCU410(GA) full phase [--] data in 1Q 2026."
X Link 2025-11-05T14:42Z [----] followers, [----] engagements
"$ocgn We saw patient going blind after patient go in and get treated. Then we saw tearful and joyous testimonials every year since. 100% efficacy. 100% safety. And thats not just one product. Were seeing it platform wide RP Stargardt GA and now autism looks to be next. Got our eyes on Alzheimers Parkinsons and more too. You can see a pre Rev bio just another speculative play or try to gamble on the SP as it fluctuates cents daily. Im seeing reality and science tell a once in a lifetime story and cant help but capitalize on the most discounted bio on the market.🍻"
X Link 2025-11-06T14:05Z [----] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing